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Zusammenfassung 
 
Die Fähigkeit des Humanen Immundefizienz Virus (HIV) in Zellen verschiedener Spezies zu 
replizieren ist häufig abhängig von der An- oder Abwesenheit interagierender oder 
einschränkender zellulärer Faktoren. Restriktionsfaktoren stellen einen Teil des 
Abwehrmechanismus des Wirts gegen Pathogene dar. Die Familie der humanen APOBEC3 (A3) 
Zytidin-Deaminasen ist Teil der intrinsischen Immunität und schützt höhere Säugetiere vor viralen 
Pathogenen. A3 Proteine tragen eine oder zwei Kopien eines Zytidin-Deaminase Motivs und 
können die retrovirale Replikation inhibieren, indem sie deren Genom während der reversen 
Transkription deaminieren. Diese Inhibition wird von HIV durch das Vif-Protein überwunden, 
welches den Abbau von A3s induziert und damit deren Verpackung in Virionen verhindert. 
Obwohl ein Mitglied dieser humanen Proteinfamilie, APOBEC3C (A3C), hoch in vielen 
menschlichem Geweben und in CD4+ T-Zellen exprimiert wird, kann A3C nur vif-defizientes SIV 
(SIVΔvif), nicht aber HIVΔvif inhibieren. Ziel der vorliegenden Arbeit war es, 1.) die 
unterschiedlichen Resistenzmechanismen von HIV und SIV gegenüber A3C zu definieren, 2.) den 
Restriktionsmechanismus von A3C gegenüber SIV zu charakterisieren, und 3.) basierend auf 
einem Strukturmodel Aminosäurereste zu identifizieren, die relevant für die antivirale Aktivität von 
A3C sind. Mit der Hilfe eines dreidimensionalen Proteinmodels wurden Aminosäurereste 
prognostiziert und experimentell identifiziert, die in die Dimerisierung des Proteins oder dessen 
Verpackung in virale Partikel involviert sind. Die Ergebnisse zeigen, dass die Dimerisierung von 
A3C notwendig für dessen antivirale Aktivität gegen SIV ist. Neben der Dimerisierung wird die 
antivirale Aktivität durch Verpackung in virale Partikel reguliert. Die Verpackung von A3C beruht 
auf einer Substratbindetasche, die distal des Zink-koordinierenden enzymatisch aktiven Zentrums 
liegt. Diese Bindetasche vermittelt die RNA-abhängige Verpackung des Proteins in das knospende 
Virus. Es konnte gezeigt werden, dass der Mechanismus der A3C-vermittelten Restriktion von 
SIVΔvif nicht die Deaminierung virale ssDNA ist. Die experimentelle Untersuchung alternativer 
Mechanismen zeigte, dass A3C weder virale RNA deaminiert, noch einen signifikanten 
inhibitorischen Effekt auf die reverse Transkription von SIV hat. Daher ist anzunehmen, dass A3C 
einen zusätzlichen, nicht bekannten Restriktionsmechanismus gegen SIV besitzt. 
Ergebnisse dieser Arbeit zeigen weiterhin, dass die Resistenz von HIV gegen A3C überwunden 
werden kann. Eine A3C vermittelte Restriktion von HIV wurde durch eine N- oder C-terminale 
Fusion des viralen Proteins R (Vpr) von HIV-1 an A3C erreicht. Interessanter Weise wurden beide 
Proteine, A3C und Vpr.3C, ins Virus verpackt und waren im gleichen viralen Kompartiment, dem 
viralen Core, zu finden. Diese Daten weisen darauf hin, dass ein von HIV zusätzlich zu vif kodierter 
Faktor der A3C Aktivität entgegenwirkt. Auf der Suche nach einem derartigen Faktor, konnte die 
virale Integrase als ein Kandidat identifiziert werden. 
Weitere Experimente sind notwendig, um die Interaktion von A3C mit HIV besser zu verstehen. 
Jedoch implizieren die Ergebnisse dieser Arbeiten, dass eine Steigerung der antiviralen Aktivität 
des ubiquitär exprimierten A3C die Replikation von HIV in Patienten eindämmen könnte und so 
einen neuen Behandlungsansatz ermöglicht. 
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Summary 
 
The capability of the Human immunodeficiency virus (HIV) to replicate in cells of different species 
depends on the presence or absence of interacting or restricting cellular factors. The restriction 
factors are part of the host’s defense mechanism against pathogens. The family of human 
APOBEC3 (A3) cytidine deaminases forms part of the intrinsic immunity and protects placental 
mammals from viral pathogens. A3 proteins have one or two copies of a cytidine deaminase motif 
and can restrict retroviral replication by deamination of their genomes during reverse transcription. 
HIV counteracts this inhibition by the Vif-protein, which induces the destruction of A3s and thereby 
prevents its incorporation into virions.  
Although one member of this human protein family, APOBEC3C (A3C), is highly expressed in 
many human tissues and in CD4+ T cells, A3C does not restrict vif-deficient HIV (HIV Δvif) but is 
active against SIV Δvif. This study aimed to characterize i) the different mechanisms of resistance 
of HIV and SIV against A3C, ii) the restriction mechanism of A3C against SIV, and iii) residues 
crucial for the antiviral activity of A3C based on a structural model. With the help of a three-
dimensional protein model of A3C, amino acids residues were predicted and finally experimentally 
identified that are involved in protein dimerization and that mediate the incorporation of A3C into 
virions. The result showed that dimerization of A3C is essential for antiviral activity against SIV. 
Beside dimerization, the antiviral activity is regulated by encapsidation into viral particles. 
Encapsidation of A3C depends on the substrate binding-pocket distal from the zinc-coordinating 
enzymatic centre. This binding pocket mediates the RNA-dependent incorporation of the protein 
into budding viral particles. It was found that A3C restricts SIV Δvif without cytidine deamination of 
viral ssDNA. Therefore, alternative mechanisms were investigated. In this study the experiments 
showed clearly that A3C does neither deaminates viral RNA nor has a significant inhibitory effect 
on the reverse transcription of SIV. Thus, it is likely that A3C has a so far unknown restriction 
mechanism against SIV Δvif.  
Results of this study also show that the resistance of HIV against A3C can be overcome. An A3C 
mediated inhibition of HIV was achieved by fusing the Viral Protein R (Vpr) of HIV-1 either to the C- 
or N- terminus of A3C. Interestingly both, A3C and Vpr.3C were incorporated into viral particles and 
found to be localized in the same viral compartment, the viral core. These data indicate that HIV 
encodes a factor additional to vif to counteract the A3C activity. In search for such a viral factor, the 
viral integrase was identified as a candidate inhibitor of A3C.  
Additional experiments are required for a better understanding of the interaction of A3C with HIV. 
However, the results here implicate that enhancing the antiviral activity of the ubiquitously 
expressed A3C would likely repress HIV-1 replication in patients and thus should be considered as 
a novel approach for treatment. 
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Introduction 
 
In the year 1981 a new epidemic in human history, the acquired immunodeficiency syndrome 
(AIDS), appeared and 3 years later it was found that a novel retrovirus was the aetiologic agent. 
Infection with the Human immunodeficiency virus type 1 (HIV-1) causes a loss of CD4 positive T-
cells, thereby weakening the human immune system and enhancing the risk of future opportunistic 
infections. HIV belongs to a large family of retroviruses including simian immunodeficiency viruses 
(SIVs). HIV-1 developed at least three times in humans by three independent transmissions from 
an SIV infected chimpanzee to humans forming the HIV-1 clades M, N and O. The transmission of 
HIV between humans mostly occurs through unsafe sex and from contaminated needles from 
injection drug users. In 2008 an estimated number of 33.4 million people (UN-AIDS; WHO) in the 
world were infected with HIV while another 25 million people already died of this disease. Most of 
the infected people, in numbers 22.4 million, live in Sub-Saharan Africa. Although the expanding 
understanding of the HIV life cycle has led to the development of antiretroviral drugs like inhibitors 
of the viral enzymes protease and reverse transcriptase, there is no vaccine or cure for HIV and 
AIDS available. Currently HIV infected people are treated with the highly active antiretroviral 
therapy (HAART), a therapy that can prolong the life of infected people to a mostly normal lifespan.  
Since the discovery of HIV, much work has been done to understand the replication of HIV in 
humans and to investigate the interactions of the virus with its host. Understanding the interaction 
of the virus with host cells restriction factors is a promising new aspect in the HIV research. Host 
cell restriction factors of non-human species are able to prevent viral infections by blocking different 
steps of the viral life cycle. Adapted viruses such as HIV to human overcome these restriction 
factors through accessory gene products that counteract the antiviral restriction. The 
characterization of the molecular basis of the interaction of viral with cellular determinants can 
highlight new targets for HIV therapy. This study focuses on the molecular understanding of the 
interaction between the cellular restriction factor APOBEC3C (A3C) and HIV or SIV. 
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A| RETROVIRUSES 
Retroviruses are enveloped RNA viruses forming the family of Retroviridae. They are diploid as 
each virion contains two copies of its ssRNA genome. During replication the retroviral genome is 
reverse transcribed into DNA by the viral enzyme reverse transcriptase (RT). The viral integrase 
(IN) catalyzes the integration of viral DNA into the host cell genome. The integration of the proviral 
DNA results in a lifelong persistent infection of the host.  
The basic genome of retroviruses is composed of three genes: gag (group specific antigen), pol 
(polymerase) and env (envelope) (Fig. A-1). The provirus of all replication competent retroviruses is 
flanked by LTRs (long terminal repeats).  
 
Fig. A-1: Schematic overview of the genome organization of a simple retrovirus. LTRs are depicted in light 
grey, in dark grey the genes gag, pol and env are shown with their protein products (white letters). The primer 
binding site (PBS) is shown as small bar. (Figure modified from Malim, M., 2009) 
 
The gag gene encodes for structural proteins of the virus: matrix (MA), capsid (CA) and 
nucleocapsid (NC). The genetic information for the viral enzymes protease (PR), reverse 
transcriptase (RT), RNaseH (RH) and integrase (IN) is located on the pol gene. The two envelope 
proteins encoded by the env gene are the surface glycoprotein (SU) and the transmembrane 
glycoprotein (TM).  
 
 
Fig. A-2: Composition of a mature retroviral particle. The dimeric RNA genome together with a cellular tRNA 
and the viral enzymes IN and RT is surrounded by CA proteins build the viral core. A layer of MA proteins 
separates the core from the envelope proteins (SU and TM). 
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The viral particle contains a dimer of the viral ssRNA as well as host cell RNA (Fig.2). This host cell 
RNA is a transfer RNA (tRNA) which is bound to the PBS of the viral RNA. The tRNA is required for 
the initiation of reverse transcription. Some viral proteins are associated with the RNA, such as NC 
that coats the RNA and the viral enzymes IN and RT. A layer of capsid (CA) proteins forms the viral 
core casing this ribonucleic acid-protein (RNP)-complex. The capsid proteins are surrounded by a 
layer of MA-proteins building a border between CA and envelope proteins. The envelope of 
retroviruses is build of two, non-covalently linked proteins, a TM protein and the heavily 
glycosylated SU protein which is the ligand for the cellular receptors and responsible for the 
recognition of the target cell. The retroviral life cycle will be illustrated using the Human 
immunodeficiency virus (HIV) by way of example. 
 
 
B| HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
HIV is a complex retrovirus that belongs to the genus of Lentiviruses. In addition to the basic 
retroviral genes gag, pol and env the HIV genome encodes for accessory genes as shown in Fig. 
B-1. The gene products of these accessory genes play important roles in the HIV life cycle as they 
either directly support viral replication like (Tat or Rev) (1-3) or counteract host cell restriction 
factors (like Vif or Vpu) (4, 5). The biological relevant functions of Vpr and Nef are less clear. 
 
 
Fig. B-1: Schematic representation of the HIV-1 genome flanked by the 5´ and 3´ LTR regions (light grey). 
Gag, pol and env genes are shown in dark grey. HIV encodes the accessory genes vif (light pink), vpr (green), 
tat (dark pink), rev (purple), vpu (blue) and nef (brown) in addition to the basic retroviral genes. The PBS is 
shown as small bar. (Figure modified from (6)). 
 
Cells of the human immune system expressing the cellular receptor CD4 (CD4+ cells), like T-helper 
cells, macrophages or dentritic cells, are the target cells for HIV infection. HIV infection can be 
separated into three steps: the acute infection, a latency phase and the progression of the Acquired 
Immunodeficiency Syndrome (AIDS) (Fig B-2). In early HIV infection the number of CD4+ cells 
dramatically drops down, either as a result of apoptosis triggered by the viral proteins Nef and Vpr 
or as a result of CD8+ T-cell recognition and killing (reviewed in (7) and (8)). During this phase of 
acute viral infection the virus spreads, being detectable through a high viral load in the plasma of 
patients. The phase of acute infection lasts for several weeks before the next stage of HIV 
infection, the latency phase, begins which in average last for years. In this phase the viral load 
decreases, due to a strong defence of the host immune system. Viral latency lasts until the number 
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of CD4+ T-cells drops below a limit where cell-mediated immunity gets lost and the progression of 
AIDS begins (reviewed in (7)). Loss of CD4+ T-cell mediated immunity enhances the risk of future 
opportunistic infections.  
 
 
Fig. B-2: The course of HIV infection. The acute infection is characterized by a high plasma viremia (red line, 
top) and a decrease in CD4+ cells (green line, bottom). After the latency phase displayed through a recovery 
of the CD4+ cells and a lowered viral load, the amount of CD4+ drops down and the number of viruses in the 
plasma increases again resulting in AIDS progression. (Figure modified from (8)). 
 
To establish preventive or therapeutic measures against HIV infections a closer look on the viral 
replication is necessary (Fig. B-3). The HIV life cycle starts with the infection of CD4+ target cells, 
either as a free virus particle or transmitted by dendritic cells within the virologic synapse. The 
binding of the HIV surface glycoprotein gp120 to a cellular CD4 receptor induces a rearrangement 
of the envelope complex allowing another domain of gp120 to attach to a chemokine receptor, 
either CCR5 or CXCR4 (9). This interaction allows gp41 to penetrate the cell membrane resulting 
in the fusion with the viral membrane (reviewed in (10)). After fusion the viral core is released into 
the cytoplasm. Prior to reverse transcription uncoating of the viral core occurs. Binding of the tRNA 
to the PBS is required for reverse transcription and the reaction is catalyzed through the viral 
reverse transcriptase (11). Viral ssRNA thereby gets transcribed into dsDNA. The nuclear import of 
the cDNA is triggered by a pre-integration complex that is transported into the nucleus via nuclear 
pores. In the nucleus the IN catalyzes the integration of the viral DNA genome into the 
chromosomal genome of the host cell resulting in the provirus formation (12). Transcription of the 
integrated provirus is initiated by cellular transcription factors that interact with the viral promoter in 
the 5´ LTR region.  
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Fig B-3: Replication cycle of HIV. Important steps are highlighted with white boxes. (Figure modified from (7)) 
 
The first viral transcripts are multiply spliced and exported from the nucleus to the cytoplasm where 
the early gene expression of Tat, Rev and Nef occurs (13). Tat and Rev both have a nuclear 
localization signal that targets them to the nucleus. Tat enhances the proviral transcription (2, 3) 
and Rev binds to unspliced or single spliced proviral RNA and thereby promotes their transport to 
the cytoplasm (1). In the cytoplasm the late gene products like Vif, Vpu, Vpr and Env are translated 
from the single spliced RNAs, whereas the unspliced RNA is translated into the gag-pol 
polyprotein. In order to facilitate the assembly of newly produced viral particles, two molecules of 
the unspliced viral RNA interact with the NC of gag-pol polyproteins which become anchored in the 
plasma membrane (reviewed in (14)). Through the recruitment of the cellular ESCRT (= endosomal 
sorting complex required for transport) proteins budding of the virion from the cellular membrane 
takes place (reviewed in (15)). Generation of an infectious viral particle (maturation) occurs after 
virus release through cleavage of the gag-pol polyproteins by the viral protease (14).  
Certain steps in the viral life cycle are targets of known host cell restriction factors. An overview of 
restriction factors with special focus on APOBEC3 proteins is given in the following. 
 
 
C| RESTRICTION FACTORS AND APOBEC3 PROTEINS 
Some cells are non-permissive for specific viruses. Non-permissivity is based on the absence of 
essential co-factors or due to the presence of factors restricting viral replication in these cells. 
These restriction factors can block viruses at different steps of the viral life cycle and adapted 
viruses have evolved strategies to circumvent these restrictions. HIV-1 is able to counteract 
Introduction 
                                                                                 8   
different restriction factors with its own accessory proteins. A lack of such a protein inhibits 
replication in non-permissive cells, but is not inhibitory in permissive cells.  
One example for a restriction factor counteracted by a viral protein is tetherin (also known as BST-
2 or CD317). This protein was first described by Neil et al 2008 (16). Tetherin-expressing cells 
were non-permissive for HIV∆vpu, whereas vpu-deleted viruses could replicate in permissive cells 
that did not express tetherin. In the absence of the viral protein U (Vpu) HIV particles are tethered 
at the cellular membrane and viral release is impaired. Although it was observed, that Vpu down- 
regulates cellular tetherin levels (17-19) and that both proteins show physical interaction (17), it 
remains unclear by which exact mechanism Vpu counteracts the restriction of tetherin. Additionally, 
lentiviruses that do not encode Vpu can also counteract the tetherin mediated restriction. In the 
case of HIV-2, a Vpu-like activity is encoded in its Env glycoprotein (20-22) and the Simian 
immunodeficiency virus from African Green Monkeys (SIVagm) and from Macaques (SIVmac) are 
able to circumvent the tetherin restriction via their Nef proteins (23, 24). Another example for a 
complex and diverse virus-host cell interaction is the family of APOBEC3 restriction proteins, which 
are subject of this study. 
 
 
Fig. C-1: Schematic representation of the human APOBEC protein family. The Zn2+ -coordinating motifs are 
shown in red and the crucial, Zn2+ - binding amino acids are highlighted. (Figure taken from (25)) 
 
The family of APOBEC3 (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3) 
restriction factors was identified through the observation, that ∆vif HIV was able to infect the cell 
line CEM-S (permissive) but not the CEM-SS cell line (non-permissive) (26). This observation led 
to the idea of a restriction factor that is expressed in the non-permissive CEM-SS cells and can be 
inactivated by the Vif protein of HIV, because wildtype (wt) HIV was able to replicate in CEM-SS 
cells. Screening of the expression profiles of these near-isogenic cell lines resulted in the 
identification of the protein APOBEC3G (A3G). This cytidine deaminase was expressed in CEM-SS 
cells, but not in the permissive CEM-S cells. A3G is a member of the human APOBEC cytidine 
deaminase family that consists of 11 members shown in Figure C-1.  
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Although this family is very homologous sharing one or two Zn2+ coordinating domains the proteins 
exhibit different enzymatic activities. APOBEC1 (A1), the founder of this protein family, is described 
as a RNA deaminase expressed in gastrointestinal tissue (27). A1 deaminates the cytosine 6666 in 
apolipoprotein mRNA resulting in an in-frame stop codon (28, 29). The truncated and the full-length 
protein have different functions in the lipid metabolism. The DNA editing activity of the activation 
induced deaminase (AID) in B-cells leads to somatic hypermutation and class-switch recombination 
of antibodies, and thus plays a key role in the maturation of the natural antibody response (30-32). 
Whereas APOBEC2 was shown to be necessary for muscle development (33), the function of 
APOBEC4 (A4) is still unknown. The human APOBEC3 (A3) family has been described as antiviral 
proteins restricting retroviruses and retrotransposons. The antiviral activity of A3 proteins is 
ascribed to the deamination of cytidine to uridine of single-stranded viral DNA formed during  
 
 
Fig. C-2: APOBEC-dependent restriction of HIV infection. (a) In cells infected with wt HIV A3 proteins are 
excluded from budding viral particles due to Vif-induced proteasomal degradation. (b) A3 proteins present in 
producer cells get incorporated into Vif-deficient viral particles and deaminate the viral genome after infection 
of a target cell. (Figure taken from (25)) 
 
reverse transcription (34-37). This DNA editing either leads to non-functional viral genes as a result 
of extensive G to A hypermutation on the coding strand of viral DNA or to degradation of viral DNA 
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by the DNA base repair enzymes uracil DNA glycosylase and apurinic-apyrimidinc endonuclease 
(38). A prerequisite for this antiviral activity is the incorporation of the A3 proteins from the producer 
cell into budding virions. In most cases, A3s being present in viral particles deaminate the viral 
genome after infection of a target cell (Fig. C-2b). Besides editing other mechanisms of A3 
mediated viral restriction, like inhibition of integration or reverse transcription have been discussed 
(39-43). The Vif protein defeats the activity of A3 proteins by binding them and recruiting an E3 
ubiquitin ligase complex (44). A3 proteins get poly-ubiquitylated and subsequent degraded by the 
proteasome (5, 45)(Fig C-2a). Thus A3 proteins are no longer incorporated into viral particles and 
the virus remains fully infectious. 
Interestingly, the Vif – APOBEC3 interaction is often species-specific. Human APOBEG3G (hA3G) 
for example is recognized by the VifHIV-1, but the Vif protein of the Simian immunodeficiency virus  
 
 
Fig. C-3: A model for the evolutionary origin of human APOBEC3 genes located on chromosome 22. The 
ancestor domains of A3A, A3C and A3H are colored in green, orange and blue, respectively. Black lines 
indicate duplications within the original segment, red lines represent duplication events resulting in a 
duplicated segment and grey lines indicate no change. Black crosses symbolize gene deletions. (Figure taken 
from (46)) 
 
from African Green Monkeys (SIVagm) is not capable to induce the degradation of hA3G (47). Vice 
versa, agmA3G is only recognized by VifSIVagm, but not by VifHIV-1. The restriction phenotype of the 
individual human A3 proteins highly differs from each other. The most prominent member of the 
human APOBEC3 protein family is A3G that exhibits antiviral activity against ∆vif HIV, many other 
retroviruses and retroelements (for review (25); see table 1 and references within). A3G has two 
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Zn2+ coordinating motifs, a C-terminal domain (CTD) and a N-terminal domain (NTD), with different 
activities (48-50). While the NTD is required for its incorporation into viral particles, the CTD 
catalyzes the deamination of the viral genome. Another member of the A3 protein family, A3C, 
contains only one Zn2+ coordinating domain and is not active against ∆vif HIV, but shows a robust 
restriction of ∆vif SIV (51) and Long Interspersed Element-1 (LINE-1) retrotransposons (52). 
Whether A3 proteins have one or two domains is a result of gene-duplications and –deletions from 
3 ancestor A3 proteins A3Z1, A3Z2 and A3Z3 (46)(Fig. C-3). 
Interestingly, the ancestor domain of A3C, A3Z2, is present in each of the two-domain APOBEC3 
proteins, showing that A3C is an evolutionary highly conserved protein. Additionally, it is broadly 
expressed in many human tissues (53), a variety of cancer cell lines (54) and is up regulated in 
CD4+ cells, the target cells of HIV (55). As HIV is able circumvent the A3C mediated restriction also 
in absence of its Vif protein (51), there is likely an additional factor encoded by HIV that can 
counteract the antiviral activity of A3C. Through these observations A3C has become an interesting 
candidate to explore virus-host interactions.  
 
D| SCOPE OF THIS WORK  
This study aimed to understand the interaction of the restriction factor APOBEC3C with HIV and 
SIV. Therefore residues of A3C crucial for its antiviral activity were identified based on a structural 
model, the different restriction phenotypes of A3C against HIV and SIV and putative mechanisms 
of antiviral restriction were analyzed. In the different chapters the following questions were 
answered or aimed to answer: 
CHAPTER I:  Which amino acids and protein structures are crucial for the antiviral activity of 
  A3C against SIV ∆vif? 
CHAPTER II:  Why is A3C antiviral against SIV ∆vif, but not against HIV ∆vif? 
CHAPTER III: What is the restriction mechanism of A3C against SIV ∆vif and is the Zn2+- 
coordinating domain the enzymatic active site of the protein? 
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ABSTRACT 
Human APOBEC3 (A3) proteins form part of 
the intrinsic immunity to retroviruses. 
Carrying one or two copies of a cytidine 
deaminase motif, A3s act by deamination of 
retroviral genomes during reverse 
transcription. HIV-1 overcomes this inhibition 
by the Vif-protein, which prevents 
incorporation of A3 into virions. In this study, 
we modeled and probed the structure of 
APOBEC3C (A3C), a single-domain A3 with 
strong anti-lentiviral activity. The three-
dimensional protein model was used to 
predict the effect of mutations on antiviral 
activity, which was tested in a Δvif SIV-
reporter-virus assay. We found that A3C-
activity requires protein dimerization for 
antiviral activity against SIV. Furthermore, by 
using a structure-based algorithm for 
automated pocket extraction we detected a 
putative substrate binding-pocket of A3C 
distal from the zinc-coordinating deaminase 
motif. Mutations in this region diminished 
antiviral activity by excluding A3C from 
virions. We found evidence that the small 
5.8S RNA specifically binds to this locus and 
mediates incorporation of A3C into virus 
particles. 
 
KEY WORDS 
Bioinformatics, immunodeficiency, protein-
protein interaction, protein structure, 
retrovirus 
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INTRODUCTION 
One of the best-characterized cellular 
proteins efficiently restricting Human 
immunodeficiency virus type-1 (HIV-1) is 
APOBEC3G (A3G) (1). Encapsidation of A3G 
in HIV-1 virus particles leads to deamination 
of cytosine residues to uracil in growing 
single-stranded DNA during reverse 
transcription (2-6). A3G has additional, still ill-
defined antiviral activities (7). HIV-1 uses the 
viral infectivity factor (Vif) to prevent or 
reduce incorporation of A3G into progeny 
virions (4, 8, 9).  
The human genome contains seven 
APOBEC3 (A3) genes which can be 
classified according to the presence of the 
Z1, Z2 and Z3 zinc-coordinating motifs (10, 
11). Z2, the A3C family, consists of A3C, the 
C- and N-terminal domains of A3DE and 
A3F, and the N-terminal domains of A3B and 
A3G. The Z1 group, the A3A family, contains 
A3A and the C-terminal domains of A3B and 
A3G. A3H represents the Z3 zinc-finger 
domain. Accordingly, A3B, A3G, A3DE and 
A3F have two domains, while A3A, A3C and 
A3H possess only one domain (12). In the 
human A3 locus there is evidence for gene 
expansion, and it was speculated that 
duplications of single-domain genes led to 
the evolution of the two-domain A3s (13). 
Phylogentic analysis of primate and non-
primate antiviral cytidine deaminases showed 
that in the early evolution of mammals genes 
for A3C (Z2), A3A (Z1) and A3H (Z3) were 
already present (11). Among these antetype 
A3s, human A3A and most variants of A3H 
are not antiviral against HIV (14-16). While 
A3C is packaged into Δvif HIV with a weak 
antiviral effect (17), A3C is a strong inhibitor 
of Δvif SIV (18). The study of A3C gains 
further importance from the fact that for A3s 
until now only structures of Z1-derived 
domains, e.g. A3G-CD, have been solved 
experimentally. Notably, both A3C and the 
still ill-defined N-terminal domain of A3G are 
of type Z2. A study by Bourara et al. (19) 
shows that in target cells A3C can induce 
limited G-to-A mutations in HIV. These 
mutations do not block viral replication, but 
rather contribute to viral diversity.  
Fundamental biochemical aspects of the A3 
protein structure and their relevance for 
antiviral activity are still a matter of 
discussion. Here, we performed comparative 
protein modeling of A3C, and assessed the 
model using A3C-mutants in the SIVagm 
system. This study provides a first structural 
basis for rational antiviral intervention 
targeting A3C. We found evidence that A3C 
dimerization is critical for antiviral activity. 
Furthermore, we found a previously 
undescribed cavity in A3C that is similar to 
nucleic acid binding pockets of known 
enzymes. A point mutation near the pocket 
diminishes encapsidation of A3C and 
reduces 5.8S-RNA-binding. We hypothesize 
that the natural substrate of this pocket of 
A3C is a nucleic acid, possibly mediating its 
incorporation into the virion by interaction 
with nucleocapsid protein. 
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RESULTS 
Comparative modeling of A3C 
Structures of APOBEC2 (A2) and A3G, C-
terminal domain (A3G-CD), have been 
solved experimentally (20-23). A2 crystallizes 
as a homo-tetramer (PDB identifier: 2NYT, 
2.5 Å resolution), composed of two outer and  
two inner monomers, forming a dimer of 
dimers, each of whose β-strands form an 
extended β-sheet. Each monomer possesses 
one copy of the conserved deaminase motif 
H-X-E-X23-28-C-X2-4-C coordinating one 
catalytic Zn2+-ion. While the overall 
conformations of the inner and outer 
monomers − chains A and C, B and D − differ 
only slightly (0.2-1.1 Å pairwise root mean 
square deviation (RMSD)), the orientation of 
E60 with respect to the Zn2+ differs 
remarkably, possibly representing a 
molecular switch between the active (outer 
monomers) and inactive (inner monomers) 
conformation (22). We thus choose chains B 
and D as possible templates for comparative 
modeling. Since several residues are not 
resolved in chain D, chain B was chosen as 
the template for the A3C model. 
Recently, two solution structures (PDB 
identifiers 2JYW, 2KBO) and a crystal 
structure (PDB identifier 3E1U, 2.3 Å 
resolution) of A3G-CD have been obtained 
(20, 21, 23). Superposition of A2 and the 
crystal structure of A3G-CD (21) reveals the 
common fold of the two polypeptides despite 
their relatively low sequence identity (< 30%) 
(Fig. 1). Notably, in the solution structure of 
A3G-CD, one β-strand adopts a loop 
conformation (20). As this segment is 
anticipated to be involved in domain 
dimerization in native full-length A3G, it has a 
limited suitability as a template structure for 
comparative modeling of A3C. 
Stereochemical quality was higher in the A2 
structure (Fig. S1). As we anticipate A3C to 
form oligomers and A3G-CD was crystallized 
as a monomer, while A2 has been 
crystallized as a tetramer, oligomerization 
properties might be better represented by 
native A2 as a template than by A3G-CD. 
Modeling of A3C on both templates at the 
same time led to poor stereochemistry of the 
resulting models, which could not be resolved 
by geometry optimization (data not shown). 
Alignments of A2 and A3G-CD to A3C were 
carried out using MODELLER (24), explicitly 
considering structural information of the 
templates (Fig. S2). We yielded favorable 
BLAST (25) e-values (A3C to A2: 6×10-23, 
A3C to A3G-CD: 10-30; BLOSUM62). All 
residues involved in the Zn2+ coordination are 
conserved in both alignments. Insertions and 
deletions were placed in loop regions. 
Alignments are supported by matching 
secondary structure predictions (PSIPRED 
(26)) to those from the crystal structures 
(data not shown). For both models, there is 
no correspondence in the templates for the 
N-terminal amino acids of A3C, so this region 
had to be constructed without template. 
Residue conservation was mapped back to 
the templates (Fig. 1a, c) and is substantially 
higher in the protein core and around the 
Zn2+-coordinating center, showing a striking 
pattern of alternating conserved / non-
conserved residues in buried / exposed parts 
of both α-helices (conserved: i, i+3, ...) and β-
strands (conserved: i, i+2, ...).
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Fig. 1. (A). Structure of A2, chain B. Conserved residues in A3C are shown in blue. Black sphere: catalytic 
Zn2+-ion. (B) Superposition of A2 (white) and A3G, catalytic domain (A3G-CD, orange). Loop regions are not 
shown. (C) Structure of A3G-CD. Residues conserved in A3C are shown in blue. 
 
Ten initial models were built for each 
template, energy-minimized and evaluated 
for robustness (27). For each of the 
templates, the model with the fewest 
violations of the stereochemistry was 
comparable to the quality of the template 
structures (Fig. S1, Fig. S3) and subjected to 
three independent runs of 20 ns molecular 
dynamics (MD) simulations (Fig. S4). 
Convergence of RMSD and energy 
parameters suggested the fold to be stable 
(Fig. S5). Identical protocols were applied for 
the template structures, also showing 
convergence. Simulated B-factors were 
calculated from the trajectories for the 
template structures as described (28), 
averaged for each system and compared to 
the experimental B-factors reported for the X-
Ray structures (r = 0.68 for A2, r =  0.76 for 
A3G-CD, Fig. S5), suggesting the dynamics 
of the structure to be well captured by our 
MD simulation (29). Taken together, these 
results suggest that both models of A3C are 
valid from a structural point of view and thus 
useful to deduce further hypotheses.  
While the two minimized models show a 
moderate pairwise RMSD of 2.7 Å (without 
the N-terminal amino acids in the loop region 
preceding the β-sheet), all residues 
considered in this study are located at 
overlapping positions (RMSD 0.7-1.4 Å) in 
the two models within precision expected 
from given levels of sequence identity and 
thus are practically equivalent (Fig. 2). Here, 
only the model structure of A3C based on the 
structure of A2 is shown. All experiments 
conducted in this study have been replicated 
with the A3G-CD-based model without 
significant change of predictions (data not 
shown). 
 
Fig. 2. Superposition of model of A3C, derived 
from A2 (white) and A3G-CD (orange). Residues 
shown to be of functional importance in this study 
are shown in red. 
  
A3C functions as a dimer. 
For A3C, which possesses only one domain, 
it is reasonable to assume a mode of 
dimerization analogous to that of A2, where 
the β-strands of two monomers build a single 
extended sheet. We would assume a similar 
mode of domain interaction in full-length 
A3G. We posed the questions whether i) A3C 
oligomerizes, and ii) there is differential  
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Fig. 3. (A) Dimerization pose of A2 (experimental, white) and A3C (predicted by ClusPro, blue). Loop regions 
are not shown. (B) Residues in the predicted dimerization interface of A3C (red) were mutated to alanine. (C) 
Immunoblot analysis of the expression and Vif-dependent degradation of wild-type(wt) A3C and different 
dimerization mutants (K51A, F55A, W74A). A3C constructs were detected by an anti(α)-HA antibody. Tubulin 
(Tub) served as loading control. (D) Antiviral activity of dimerization mutants F55A, W74A, K51A and wt A3C 
against SIVagm, compared to non-transduced cells (no virus) and vector only control without A3C. wt or Δvif 
SIVagmluc (VSV-G) virions were generated by co-transfection with the respective A3C mutant. Virions were 
normalized by RT activity. Luciferase activity was measured 3 days post infection. 
 
activity between the monomeric and 
oligomeric forms. 
First, protein-protein interaction interfaces 
were predicted using ProMate (30). Amino 
acids corresponding to the A2 dimerization 
interface were highlighted as potentially 
involved in the interaction. The protein 
docking and clustering technique ClusPro 
(31) accurately reproduced the A2 dimer 
(RMSD = 1.7 Å), and was applied to 
generate an A3C dimer model in silico (Fig. 
3a). The overall topology of both the A2 and 
A3C dimer models is similar.  
Selected amino acids in the predicted 
dimerization interface of A3C were mutated. 
As exposed aromatic amino acids often 
participate in protein-protein-interaction (32), 
two prominent aromatic amino acids (F55, 
W74) and K51, possibly contributing to 
electrostatic interactions, were mutated to 
alanine (Fig. 3b). All constructs (K51A, F55A, 
W74A) were expressed, showing wt-like 
degradation in presence of Vif (Fig. 3c). To 
determine whether these A3C-mutants 
display antiretroviral activity, virions were 
generated by co-transfection with A3C 
expression plasmids. In transduced cells, 
A3C and K51A reduced the infectivity of the 
Δvif SIV ~90-120-fold, F55A and W74A 
showed a clearly diminished inhibitory activity 
(~2-4-fold inhibition of Δvif viruses) (Fig. 3d). 
In contrast, wt SIV was not inhibited by any of 
the A3C-mutants. Inhibition of Δvif SIV by wt 
A3C and K51A was shown to be dose-
dependent, whereas F55A and W74A were 
still inactive although using highest amounts 
of expression plasmid (Fig. 4). 
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Fig. 4. (A) Immunoblot analysis of the dose-dependent expression in 293T cells and encapsidation in viral 
particles of wt A3C and different dimerization mutants (F55A, W74A and K51A). pcDNA, transfection control; 
vector, wt SIVagm without A3C. The respective amounts of the A3C constructs were detected by an anti(α)-
HA antibody. Tubulin (Tub) and capsid (p27) served as loading control. (B) Dose-dependent antiviral activity 
of dimerization mutants F55A, W74A and K51A against SIVagm Δvif, compared to wild-type(wt)-
huAPOBEC3C (A3C) and background of non-transduced cells (no virus) and vector only control (vector) 
without A3C. Δvif SIVagm luc (VSV-G) virions were generated by co-transfection with the indicated amount 
(µg) of the respective A3C mutant. Virions were normalized by RT activity and used for transduction. 
Luciferase activity (in counts per second, cps) was measured 3 days post infection. 
Packaging of A3 into the virion is crucial for 
its antiretroviral activity (4, 8, 9). To 
determine whether missing encapsidation of 
the inactive mutants, is responsible for the 
absence of inhibition, virions were generated 
and analyzed for A3C content by immunoblot 
analysis. Fig. 5a shows that all mutants were 
efficiently packaged, comparable to wt A3C. 
To determine whether oligomerization of the 
mutant proteins correlates with antiretroviral 
activity, expression vectors for V5-tagged wt 
A3C were co-transfected with expression 
plasmids for HA-tagged A3Cs (wt or 
mutants). F55A and W74A barely 
precipitated V5-tagged wt A3C. In contrast, 
K51A and HA-tagged wt A3C were able to 
precipitate V5-tagged wt A3C (Fig. 5b). 
Quantification of the precipitated V5-tagged 
wt A3C in presence of wt A3C compared to 
W74A resulted in a significant higher binding 
efficiency (~10 fold, Fig. S6). W74A-HA co-
precipitated the V5-tagged wt A3C only very 
weakly. Crosslinking of wt A3C in total cell 
lysate of transfected cells showed 
monomeric, dimeric and tetrameric forms, 
whereas W74A only formed monomers and 
dimers (Fig. S6). We postulate that the W74A 
mutation in the dimerization interface 
prevents the formation of the inner dimer, but 
does not influence the formation of the outer 
dimer. This correlates with the observation of 
a weaker binding activity seen in 
immunoprecipitation assuming that the inner 
dimer is more stable, where as the outer  
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Fig. 5. (A) Immunoblot analysis of A3C packaging. 
293T cells were co-transfected with SIVagm Δvif 
luc (VSV-G), the respective HA-tagged A3C 
construct (mutants F55A, W74A, and wild-type 
(wt)). Virions were harvested and normalized by 
RT. Physically equal amounts of virions were 
lysed and subjected to immunoblot analysis. 
Presence of A3C in the virons was detected using 
anti(α)-HA-antibodies. p27 (capsid) served as 
loading control. (B) Immunoblot analysis of A3C 
dimerization. 293T cells were co-transfected with 
the respective HA-tagged A3C construct (mutants 
K51A, F55A, W74A, and wt) and V5-tagged wt 
A3C. Immune precipitates (IP) were subjected to 
immunoblot analysis. Proteins were probed using 
α-HA- / -V5-antibodies, respectively. Tubulin (Tub) 
served as loading control in cell lysates. 
 
dimer gets disrupted during the washing 
steps. These results indicate that F55 and 
W74 participate in dimerization of A3C, and 
that oligomerization is crucial for antiviral 
activity of the enzyme. It is noteworthy that 
the dimer mutants did not exhibit DNA editing 
activity in an E. coli mutation assay 
(compared to wt A3C, Fig. 6), which is in 
perfect agreement with the requirement for 
dimeric protein for enzymatic activity. 
 
 
A cavity of A3C mediates its 
encapsidation. 
Enzyme-substrate interactions typically occur 
over well-defined protein binding pockets, 
where the active site typically is one of the 
largest cavities of the protein (33). Our 
software PocketPicker (33) was employed to 
identify potential ligand binding pockets in the 
A3C model. The presumed active site was 
found to be the 5th biggest cavity in the A2-
based structure (A3C/A2) (~80 Å3). The 
largest cavity (~200 Å3) is found 15 Å apart 
from the Zn2+ ion and has not yet been 
described in literature (Fig. 7a). The A3G-
CD-based model structure of A3C contains a 
similar binding pocket (Fig. 7b).  
 
 
Fig. 6. Editing activity of wt and mutant A3C 
proteins measured as RifR colonies per 109 viable 
cells in E. coli mutation assay. 
 
Four residues near this pocket were mutated 
to alanine: K22, T92, R122, and N177 (Fig. 
7c). Co-expression of these mutants with Vif 
demonstrated protein degradation similar to 
wt A3C (Fig. 8a). To test whether mutant 
A3C-proteins inhibit virus replication, wt and 
Δvif SIV were generated by co-transfection 
with A3C expression plasmids. Wild-type 
A3C as well as its mutants K22A, T92A, and 
N177A inhibited Δvif SIV (~60-84-fold) but 
not wt SIV (Fig. 8b). In contrast, the mutant  
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Fig. 7. (A) Model structure of A3C, derived from A2 (white). The binding pocket distal to the Zn2+-ion (black 
sphere) is indicated in blue, R122 in red. (B) Model structure of A3C, derived from A3G-CD (orange). The 
binding pocket is indicated in blue, the Zn2+-ion in black, R122 in red. (C) To test the function of this protein 
cavity, residues in red were mutated to alanine. 
 
R122A lost the inhibitory activity. Immunoblot 
analysis of A3C content in viral particles 
showed a greatly reduced packaging of 
R122A compared to A3C wt and K22A, 
T92A, N177A (Fig. 8c), although it was 
detectable in cell lysates (Fig. 6a). By fusing 
VPR to R122A the mutant could be re-
targeted into viral particles and showed 
antiviral activity (Fig. 8d, e). In addition, 
R122A showed DNA editing activity in 
bacteria (Fig. 6). We conclude that R122 is 
critically relevant for particle packaging but 
not for antiviral activity of A3C. 
In search for potential ligands of this 
presumed binding pocket, it was compared to 
pockets extracted from the PDBBind (34) 
collection with known protein function and 
ligands. The four hits that were identified as 
most similar stem from human papillomavirus 
(HPV) type 11 E2 transactivation domain 
(TAD) complex (PDB identifier: 1R6N), a 
DNA binding protein of HPV; and three holo-
structures of bovine RNase A (PDB 
identifiers: 1QHC, 1JN4, 1O0M), co-
crystallized with different nucleotides. For the 
A3C/A3G-CD pocket, four holo-structures of 
bovine Rnase A (PDB identifiers: 1U1B, 
1W4P, 1O0M, 1QHC) were among the eight 
top scoring pockets. The natural substrates 
of these pockets are nucleic acids: ds DNA 
for HPV 11 E2 TAD, and ss and dsRNA for 
bovine RNase A. Steric and electrostatic 
properties of the hypothesized pocket in A3C 
would allow for nucleic acids as a substrate, 
possibly by R122 interacting with the 
negatively charged sugar-phosphate 
backbone.  
To test for RNAs interacting with this binding 
pocket, wt A3C and R122A were precipitated 
from transfected cells, interacting RNA was 
isolated and detected by 32P-labelling (Fig. 
8f). Mutation of R122 resulted in strongly 
decreased amounts of RNA bound to the 
protein compared to wt A3C or a C98S active 
site mutation. The isolated RNA was further 
subjected to RT-PCR to amplify 7SL or 5.8S 
RNA (Fig. 8g). A3C wt protein showed an 
interaction with 7SL and 5.8S RNA, while the 
mutant R122A lost the binding to 5.8S RNA. 
Furthermore, RNA binding was shown to be 
crucial for interaction of A3C to SIV-
nucleocapsid (NC). A3C wt interacts in a 
RNA-dependent manner with SIV-NC, while 
R122A exhibits no binding activity (Fig. 9). 
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Fig. 8. (A) Immunoblot analysis of the expression and Vif-dependent degradation of wild-type(wt) A3C and the 
mutants K22A, T92A, R122A, N177A. The respective A3C constructs were detected by an anti(α)-HA 
antibody. Tubulin (Tub) served as loading control. (B) Antiviral activity of the mutants K22A, T92A, R122A and 
N177A against SIVagm, compared to wt A3C and background of non-transduced cells (no virus) and vector 
only control (vector) without A3C. 293T cells were co-transfected with wt or Δvif SIVagmluc (VSV-G), 
respectively, and the respective A3C mutant. Virions were normalized by RT and HOS cells transduced. 
Luciferase activity was determined at 3 days post infection. (C) Immunoblot analysis of A3C packaging. 293T 
cells were co-transfected with Δvif SIVagmluc(VSV-G), the respective HA-tagged A3C construct (mutant R122A 
and wt). Virions were harvested and normalized by RT. Physically equal amounts of virions were lysed and 
subjected to immunoblot analysis. Presence of A3C in the virons was detected using α-HA-antibodies. p27 
(capsid) served as loading control. (D) Antiviral activity of Vpr-A3C and Vpr-R122A fusion proteins against 
SIVagm, compared to wt A3C and R122A and background of non-transduced cells (no virus) and vector only 
control without A3C. Δvif SIVagmluc (VSV-G) virions were generated by co-transfection with the respective A3C 
mutant. Virions were normalized by RT activity and used for transduction. Luciferase activity was measured 3 
days post infection. (E) Immunoblot analysis of the expression and encapsidation of wt A3C and R122A 
compared to the respective Vpr-fusion-proteins. A3C constructs (+ or – Vpr) were detected by an anti(α)-HA 
antibody. Tubulin (Tub) served as loading control for cell lysates and p27 (capsid) for viral lysates. (F) RNA 
interacting with A3 proteins. A3C wt or mutant proteins and wt A3G were expressed in 293T and cell lysates 
were subjected to immuno precipitation. RNA bound to immunoprecipitated proteins was radioactively labeled 
with 32P through RT-PCR and separated on a 12% PAA Gel and exposed on X-ray film. Background was set 
to signal of untransfected cells (mock). Equal amount of precipitated A3 protein was proven by immunoblot 
analysis of the elution fraction with an anti(α)-HA antibody. (G) RT-PCR on RNA interacting with A3 proteins. 
Isolated and A3 bound RNA (IP) was reverse transcribed and amplified using specific primers for 7 SL and 5.8 
S RNA. Background signal was determined with RNA from untransfected cells (mock). Availability of the 
tested RNAs was confirmed for each sample through RT-PCR on RNA from cells prior to IP (cells). 
  
We conclude that the large pocket detected 
on the surface of A3C plays a key role in 
incorporation of A3C into viral particles, 
mediated by RNA-dependent interaction with 
SIV-NC. 
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DISCUSSION 
We have presented two three-dimensional 
models of A3C derived by comparative 
protein structure modeling taking the crystal 
structures of A2 and the catalytic domain of 
A3G as templates. These models were used 
to deduce hypotheses regarding dimerization 
and to characterize a presumed substrate 
binding pocket of A3C. Although sequence 
identity between A2 and A3C falls into the 
“twilight zone” (35, 36), homology between 
A2 and A3C can be assumed due to the 
conservation of the Zn2+-coordinating 
domain, the comparable class of enzyme 
function, and predicted similar secondary 
structure. The stereochemical quality of 
energy-minimized models of A3C was 
comparable to that of the templates, and 
folding stability was demonstrated by MD 
simulations. The level of sequence identity of 
the templates to the targets a priori indicates 
an expected medium accuracy of the model 
(~85% of residues within 3.5 Å of the actual 
conformation), rendering them suitable to 
support site-directed mutagenesis 
experiments (37), although predictions 
requiring exact side chain orientations cannot 
be made. 
 
 
Fig. 9. Immunoblot analysis of A3C interaction with nucleocapsid (NC) from SIVagm. 293T cells were 
transfected with A3C wt or R122A expression plasmids and incubated with GST or GST-NC expressed in E. 
coli. After RNaseA treatment and immunoprecipitation, bound proteins were subjected to immunoblot analysis. 
Proteins were detected using anti-HA mAb or anti-GST mAb, respectively. Equal expression of wt A3C and 
R122A in 293T cells was confirmed (input). 
 
Using an automated approach we suggest a 
potential substrate binding pocket in A3C, 
which is distal from the Zn2+-coordinating 
site. Mutation of R122 at the pocket entrance 
resulted in the loss of antiviral activity due to 
diminished incorporation of the mutated 
protein into the virion. This arginine is 
conserved in A2 A3G-CD and A3G-ND (Fig. 
S2). Packaging of A3G has been 
demonstrated to be dependent on interaction 
with 7SL RNA (38). As a mutation of R122 in 
A3C impedes the RNA-dependent NC-
interaction and the incorporation into virions 
one can speculate on R122 being important 
for RNA dependent packaging of the protein. 
With regard to the accuracy level of our 
protein model, it is possible that this binding 
pocket partially overlaps with the active site, 
resulting in a large binding pocket of bipartite 
function, similar to the substrate binding 
channel proposed for A3G-CD (21). R122 
could then be thought of interacting with DNA 
as a substrate anchor for deaminase activity.  
Both activities might be mutually 
independent, as suggested by comparing the 
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characteristics of active-site mutant C98S 
with R122A. 
Our A3C model is consistent with dimer 
formation of A3C analogous to that of A2. 
Mutations in the predicted interaction surface 
revealed that the antiviral function of A3C 
requires dimerization. In contrast to previous 
data (39), it was later shown that monomeric 
A3G is an active inhibitor of Δvif HIV (40). 
Because of the inherent dimeric character of 
A3G, which possesses two copies of the 
Zn2+-coordinating motif, additional 
dimerization of A3G might not be required for 
antiviral activity.  
Summarizing, our results demonstrate that a 
predicted binding pocket of A3C interacts 
with RNA, e.g. 5.8 S RNA, and that RNA 
interaction is required for encapsidation 
mediated by binding to NC, but not for 
antiviral activity. Why dimerization of A3C is 
critical for antiviral activity remains an open 
question and an important subject for future 
studies. 
 
During revision of this manuscript, Huthoff et 
al. (41) presented a homology model of A3G 
and demonstrated its RNA-dependent 
packaging that is determined by a residue 
inside its N-terminal domain being equivalent 
to R122 (for sequence alignment see Fig. 
S2), thereby additionally supporting our 
hypothesis. 
 
EXPERIMENTAL PROCEDURES 
Model building. Target A3C sequence, NCBI 
accession: NP_055323. Chain B of the tetrameric 
crystal structure of A2 (PDB identifier 2NYT, 2.5 Å 
resolution (22, 42)) and catalytic domain of A3G 
(PDB 3E1U, 2.3 Å resolution (21)) served as 
template. The initial sequence-alignment of A3C to 
monomeric A2, chain B, and the catalytic domain 
of A3G, was performed by the align2d function of 
MODELLER 9v4 (24, 43). Both target-template 
alignment and structural coordinates of A2, chain 
B, and A3G-CD, were used to build ten initial 
models by satisfaction of spatial restraints, 
subjected to energy minimization and MD 
simulation (Supplementary Material).  
Characterization of binding pockets. 
PocketPicker (33) was used to automatically 
identify potential binding pockets and encode 
them as correlation vectors as described (33, 44). 
Each vector was then compared to 1,300 binding 
pockets with annotated function from the “refined 
set” of the PDBBind data set (34) using the 
Euclidean distance metric.  
Mapping of functional residues. MOE 2006.08 
(Chemical Computing Group, Montreal, Canada) 
was used to calculate the solvent accessible 
surface of the protein model and map electrostatic 
properties by a Poisson-Boltzmann potential. 
Putative protein-protein interaction interfaces were 
selected manually by looking for solvent-exposed 
hydrophobic patches, and fully automated using 
ProMate (30). Protein-protein docking and 
clustering of docking poses was carried out with 
ClusPro (31). 
Plasmids. C-terminally hemagglutinin (HA)-
tagged A3C expression plasmid has been 
described (45). Viral vectors were produced by co-
transfecting pSIVagm Δvif luc (4), pMD.G, a VSV.G 
expression plasmid, and supplemented by pcVif-
SIVagm-V5 (46). For co-immunoprecipitation 
studies pcDNA3.1-APOBEC3C-V5-6xHis (47) was 
used. HA-tagged mutated A3C constructs were 
derived by fusion PCR and cloned into pcDNA 
3.1(+) (Invitrogen), using BamHI and NotI 
restriction sites. The pcVPR-A3C-HA expression 
plasmid was generated by fusion of SIVagm-VPR 
cDNA to the N-Terminus of HA-tagged wt or 
mutant A3C with a Gly4-Ser-linker and cloned into 
pcDNA 3.1(+) using the same restriction sites. The 
premature stop-codon in VPR of SIVagm_TAN-1 
was rectified by site directed mutagenesis. 
Sequences of primers in Supplementary Material. 
PCRs were performed with Phusion™ DNA 
Polymerase (Finnzymes) at: 1 cycle at 98°C, 3 
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min; 35 cycles at 98°C, 15 s; 65-71°C, 30 s; and 
72°C, 20 s; and 1 cycle at 72°C, 10 min. 
Immunoblot analysis. For analysis of expression 
of A3C-constructs, 293T cells were transfected 
with 1 µg A3C-expression plasmid and 2 µg of Vif-
expression plasmid, using LipofectamineLTX 
(Invitrogen). Two days post transfection, cells 
were harvested and lysed using Western Lysis 
Buffer (100 mM NaCl, 20 mM Tris, pH 7.5, 10 mM 
EDTA, 1% sodium deoxycholate, 1% Triton X-100, 
and complete protease inhibitor (Roche)). Lysates 
were cleared by centrifugation and subjected to 
SDS-PAGE followed by transfer to a PVDF 
membrane. A3C-HA-constructs were detected 
using an anti (α)-HA antibody (1:104 dilution, 
Covance) and α-mouse horseradish peroxidase 
(1:7,500 dilution, Amersham Biosciences). For 
detection of Vif-V5 or A3C-V5, an α-V5 antibody 
(1:4,000 dilution, Serotec) was applied. α -tubulin 
was detected using an α-tubulin antibody (1: 104 
dilution, Sigma). Signals were visualized by ECL 
plus (Amersham Biosciences). 
Packaging of A3C. To detect A3C in virions, A3C 
expression constructs were co-transfected with 
pSIVagm Δvif luc and pMD.G in 293T cells, as 
described above. Particles were precipitated by 
ultracentrifugation over a 20% sucrose cushion, 
normalized for activity of reverse transcriptase and 
lysed using Western Lysis Buffer. Lysates were 
directly subjected to SDS-PAGE and transferred 
to a PVDF-membrane. p27 was detected using a 
p24/p27 monoclonal antibody AG3.0 (1:250) (48).  
Co-immunoprecipitation. To detect protein 
interaction, expression plasmids of the respective 
proteins were co-transfected into 293T-cells. Cells 
were lysed in ice cold lysis buffer (25mM Tris (pH 
8.0), 137mM NaCl, 1% Glycerol, 0.1% SDS, 0.5% 
Na-deoxycholat, 1% NP-40, 2mM EDTA and 
complete protease inhibitor cocktail (Roche)). The 
cleared lysates were incubated with 30 µL α-HA 
Affinity Matrix Beads (Roche), 60 min, 4°C. The 
samples were washed 5 times with ice cold lysis 
buffer. Bound proteins were eluted by boiling the 
beads for 5 min at 95°C in SDS loading buffer. 
Immunoblot analysis and detection was done as 
described. Light units of the elution fractions were 
directly quantified from membranes incubated with 
ECL plus using the Lumianalyst 3.0 software 
(Roche).  
Reporter virus assay. To measure antiretroviral 
activity of A3C-constructs, expression plasmids 
were co-transfected to 293T cells with pSIVagmΔvif 
luc, pMD.G, in presence and absence of a Vif 
SIVagm expression plasmid. Two days after 
transfection, supernatants were harvested, 
normalized by RT activity and transduced 2 × 103 
HOS cells in a 96-well dish. Three days after 
transduction, intracellular luciferase activity was 
quantified using Steady Lite HTS (Perkin Elmer). 
Data are presented as the average counts/second 
of the triplicates ± standard deviation. RT activity 
was quantified using the Lenti-RT Activity Assay 
(Cavidi Tech). The cell lines 293T and HOS were 
cultured in Dulbecco’s high glucose modified 
Eagle’s medium (Invitrogen), 10% fetal bovine 
serum, 0.29 mg/ml L-glutamine, and 100 units/m 
penicillin/streptomycin at 37°C with 5% CO2. 
A3C-RNA-interaction. To detect protein-RNA 
interaction, expression plasmids of the respective 
proteins were transfected to 293T-cells as 
described above. Cells were lysed in ice cold lysis 
buffer (PBS with 1% Triton X-100, 16U/mL 
RiboLock RNase Inhibitor (Fermentas) and 
complete protease inhibitor cocktail (Roche)). The 
cleared lysates were incubated with 50 µL α-HA 
Affinity Matrix Beads (Roche), 60 min, 4°C. The 
samples were washed 5 times with ice cold lysis 
buffer. RNA bound to immobilized proteins was 
extracted from HA-beads using TRIzol reagent 
(Invitrogen) (according to the companies 
instructions). RNAs co-precipitated with A3C 
proteins were dissolved in DEPC-treated H2O and 
equal amounts were used for reverse transcription 
using random hexamer primers (Fermentas) in the 
presence of α-32P-dATP (Hartmann Analytic). 
Radioactive labeled cDNA was separated on a 
12% TBE 8M Urea PAA Gel and visualized with 
Amersham Hyperfilm (GE healthcare). Specific 
RT-PCR on A3C bound RNAs was performed 
using Reverd Aid First Strand cDNA synthesis kit 
(Fermentas) and random hexamer primers. 
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Protein-Protein-Crosslinking. For crosslinking 
experiments, expression plasmids of the 
respective proteins were transfected to 293T-cells, 
two days later cells were lysed and whole cell 
lysate was incubated with 50mM N-Ethylmaleimid 
(NEM/Calbiochem) for 2hrs at RT. Immunoblot 
analysis was performed as described above but 
no DTT or β-mercapthoethanol was added to the 
SDS-loading buffer during electrophoresis. 
E. coli mutation assay 
Uracil DNA glycosylase-deficient E. coli strain 
BW310 was transformed with isopropyl 1-thio-β-D-
galactopyranoside (IPTG) - inducible APOBEC3 
expression constructs (APOBEC3 encoding cDNA 
was inserted in pTrc99A using XhoI and SalI 
restriction sites) or pTrc99A empty vector. 
Individual colonies were picked and grown to 
saturation in a rich medium containing 100µg/ml 
ampicillin and 1 mM IPTG. Appropriate dilutions 
were plated onto a rich medium containing 
100µg/ml rifampicin to select RifR colonies after an 
overnight incubation. Mutation frequencies were 
reported as the number of RifR colonies per 109 
viable cells. 
A3C – NC interaction 
Plasmids: A bacterial plasmid (pGEX-p2NCp1-
SIVtan) expressing p3:NC:p1 fused to GST on its 
N-terminus was generated by PCR amplification of 
relevant part of SIVagmTAN and subsequent 
insertion into pGEX-6P via XmaI and XhoI 
restriction sites.  
Escherichia coli (strain: BL21 DE3 Rosetta) 
transformed with pGEX-p2NCp1-SIVtan and 
parental pGEX-6p-1 were used for protein 
expression. Cells were harvested 5 h post 
induction with 100 µM IPTG (Fermentas), lysed by 
sonification in PBS supplemented with 1 % NP 40 
and protease inhibitor coctail (Calbiochem). 
Glutathione sepharose beads (GE Healthcare) 
were incubated with clarified lysates for 30 min at 
25 °C, washed 3 times with lysis buffer (10fold 
beads volume), resuspended in 10 mM Tris pH 
7,5; 150 mM NaCl; 0,5 % NP40 with or without 34 
µg/ml RNaseA (Fermentas) and incubated for 1h 
at 37 °C. Subsequently samples were washed and 
incubated with lysates of 293T cells expressing wt 
A3C or R122A mutant over night at 4 °C in PBS, 
1% NP 40 and 300 mM NaCl. After the beads 
were washed extensively with PBS/1 % NP 40, 
proteins were eluted with 10 mM glutathione, 50 
mM TRIS (pH 8) and used for immunoblot 
analysis using anti-HA mAb or anti-GST mAb 
(1:1.000 dilution; cell signaling). 
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CHAPTER II 
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ABSTRACT 
The APOBEC3 family of cytidine deaminases 
protects vertebrates from viral pathogens. 
Human APOBEC3C (A3C) restricts the 
Simian immunodeficiency virus (SIV) in 
absence of its Vif protein, but has no antiviral 
effect against vif-deficient Human 
immunodeficiency virus (HIV Δvif). 
Our study confirmed that A3C lacks the 
ability to restrict HIV Δvif although it is 
incorporated into viral particles. This 
phenotype could be altered through fusing 
the Viral Protein R (Vpr) of HIV-1 either to the 
C- or N- terminus of A3C. Interestingly, also 
wt HIV was inhibited by the Vpr-A3C fusion 
protein indicating a block of A3C interaction 
with Vif. Exploring the sub-viral localization of 
the fusion protein compared to wt A3C did 
not show significant differences. Thus, HIV 
likely encodes for a factor which counteracts 
A3C activity additional to vif. Preliminary 
experiments indicate that the viral integrase 
(IN) acts as an A3C inhibitor. 
 
INTRODUCTION 
Although the APOBEC3 protein family is very 
homologues sharing a characteristic motif for 
Zn2+-coordination, the specificity of each 
APOBEC3 differs from the others (1). Several 
APOBEC3 proteins (e.g. A3F and A3G) 
restrict HIV replication in the absence of the 
Viral infectivity factor (Vif) protein (2, 3). 
Another member, A3C is only active against 
SIV and Long Interspersed Element-1 (LINE-
1) retrotransposons, but not against HIV (4, 
5). The inhibitory effect of A3C against SIV 
Δvif was shown to be 10-100 fold. However, 
one report described an influence of A3C on 
HIV in target cells (6). Here single G-A 
mutations could be observed in spreading 
HIV infection of cells expressing A3C. The 
authors speculate on a potential benefit of 
these mutations to the mutation rate of the 
HIV genome. The viral counterpart that 
mediates the HIV Δvif resistance against A3C 
restriction was not described yet.  
Another protein of the APOBEC3 family, 
A3A, also has no antiviral activity against 
HIV Δvif. This Vif-independent counteraction 
of HIV could be circumvented by fusing the 
Viral Protein R (Vpr) of HIV-1 to A3A (7). 
Several functions in HIV replication have 
been suggested for Vpr such as modest 
transactivation of viral transcription (8), 
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contribution to the nuclear import of the pre-
integration complex (9, 10) or induction of a 
cell cycle arrest in the G2/M phase in 
mammalian cells (11, 12). Another 
characteristic of Vpr is the interaction with the 
p6 domain of the Gag precursor polyprotein 
of HIV (13, 14). Via this interaction Vpr gets 
efficiently incorporated into HIV particles and 
enables the protein to deliver heterologous 
proteins (as Vpr fusion proteins) into the virus 
(15, 16). The fusion of Vpr to A3A resulted in 
alterations of the sub-viral localization of the 
fusion protein compared to wt A3A. The 
inactive A3A was not localized within the viral 
core whereas the antiviral active Vpr-A3A 
fusion protein was found to be part of the 
viral core thus being in close proximity to its 
potential target, the viral genome. Further, 
the fusion of Vpr of SIV of the African Green 
Monkey (SIVagm) to a packaging deficient 
R122A mutant of A3C (Vpragm.R122A) could 
rescue its incorporation (see Chapter I). 
The aim of this study was to identify whether 
the fusion of HIV-1Vpr to A3C modulates its 
restriction properties against HIV and / or 
alters the localization of A3C within the viral 
particle.  
 
Fig. 1: A3C is active against SIV∆vif, but not against HIV∆vif. (A) Antiviral activity of A3C and A3G proteins 
against SIVagm Δvif luc and HIV Δvif luc in presence (white bars) or absence (black bars) of the respective co-
expressed Vif protein compared to controls without A3 expression (HIV / SIV only). (B) Immunoblot analysis of 
the expression, Vif-dependent degradation in producer cells and incorporation into virions of HA-tagged A3C 
and A3G using an α-HA antibody. Co-expression of the respective Vif proteins of HIV and SIV is indicated with 
a plus sign (+), the absence of Vif indicates a minus sign (-). Tubulin (α-Tub) and capsid (α-CA) served as 
loading control. 
 
Chapter II 
                                                                                 32   
RESULTS 
A3C acts antiviral only against SIV∆vif 
APOBEC3G (A3G) is well described as a 
potent inhibitor of HIV ∆vif and SIV as well as 
other viruses. The antiretroviral activity of 
A3C is restricted to SIV ∆vif (5). A vif-
deficient HIV is not inhibited by A3C. As 
incorporation into viral particles during 
budding is crucial for the antiviral activity of 
APOBEC3 cytidine deaminases, we first 
examined whether the lack of restriction 
against HIV ∆vif is due to the exclusion of 
A3C from HIV particles (Fig.1). Therefore 
virions were produced in 293T cells in 
presence and absence of A3C and A3G as a 
positive control. As expected A3G restricted 
SIV in a vif-independent manner and HIV ∆vif 
was also inhibited up to 30-fold (Fig.1A). 
Immunoblot analysis of lysates from 
transfected cells showed comparable 
expression levels of A3C and A3G and a Vif-
dependent degradation of both proteins (Fig. 
1B). As expected, A3G was not degraded by 
 
Fig. 2: Schematic representation of the used 
APOBEC3 and A3C-Vpr fusion proteins. APOBEC 
proteins are shown in grey having one (A3C) or 
two (A3G) Zn2+ - coordinating motifs shown in red. 
HIV-1Vpr (blue) fused to the N- or C- terminus of 
A3C with a Gly4-Ser- linker in between.  
 
the Vif protein of SIVagm (17). In both cases 
of viral restriction A3G was incorporated into 
the viral particles (Fig.1B). HIV ∆vif was 
resistant against A3C, but unexpectedly it 
was also incorporated into viral particles. The 
A3C-mediated restriction of SIV ∆vif 
demonstrated that the deaminase was 
enzymatically active (Fig.1A).  
 
 
 
Fig. 3: Antiviral activity of wt A3C and indicated Vpr-A3C fusion proteins against HIV in presence (white bars) 
or absence (black bars) of Vif fromHIV compared to non-transduced cells (mock) and vector only control 
without A3C. Expression of the different HA-tagged proteins in producer cells was determined via immunoblot 
analysis with an α-HA antibody. Tubulin (α-Tub) served as loading control. 
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A VPR(HIV-1) - A3C fusion protein exhibits 
anti-HIV activity  
Vpr of HIV was fused to the N- and the C-
terminus of A3C (Fig. 2) via fusion PCR. In 
both cases a Gly4-Ser-linker was introduced 
to separate the different protein domains. 
The same vpr construct was also fused to the 
N-terminus of the A3C C98S mutant. C98 is 
part of the Zn2+-coordinating motif. Mutating 
only one of the 4 amino acids that 
coordinates the Zn2+-ion in the active site of 
the protein results in loss of function proteins 
(see Chapter III). Here, the Vpr.C98S 
construct served as a negative control. To 
investigate the antiviral potential of the Vpr 
fusion proteins, HIV ∆vif particles were 
produced in 293T cells in presence or 
absence of the different expression plasmids. 
Using luciferase reporter viruses, A3C 
showed no antiviral activity against HIV ∆vif, 
but both A3C Vpr fusion proteins reduced the 
infectivity of HIV ∆vif ~90-fold. (Fig. 3A). 
Interestingly, this effect was Vif-independent 
because co-expression of HIV Vif could not 
counteract the activity of Vpr.3C. This effect 
was shown to be specific, as titration 
experiments resulted in a dose-dependent 
inhibition of ∆vif and wt HIV, whereas A3C 
was inactive against HIV ∆vif at any 
concentration of used expression plasmid 
(Fig. 4). Fusion of Vpr to the C-terminus of 
A3C resulted in an even stronger inhibition of 
HIV (up to ~150-fold) in presence or absence 
of Vif (Fig. 3A). The increased antiviral 
activity of 3C.Vpr correlated with higher 
expression compared to Vpr.3C (Fig. 3B). 
The antiviral activity of 3C.Vpr was likely 
caused by an enzymatic activity of the A3C 
part of the fusion protein because fusion of 
the enzymatic inactive C98S mutant to Vpr 
did not restrict HIV (Fig. 3A). 
 
 
Fig. 4: (A) Dose-dependent antiviral activity of Vpr.3C against HIVΔvif in presence (white bars) and absence 
(black bars) of co-expressed HIV Vif, compared to wt A3C (grey bars) and vector only control without A3C. (B) 
Immunoblot analysis of the dose-dependent expression of wt A3C and Vpr.3C in producer cells. The 
respective amounts of A3C were detected by an α-HA antibody,  tubulin (Tub) served as loading control. 
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VPR-fusion does not change sub-viral 
localization  
To explore the relevance of sub-viral 
localization of A3C and Vpr.3C, VSV-G 
pseudotyped vif-deficient HIV particles were 
produced in the presence of A3C or Vpr.3C. 
After concentration through a 20% sucrose 
cushion the virions were applied to a 20-60% 
OptiPrep™gradient (Fig. 5). 
 
 
Fig. 5: Schematic representation of the 
constitution of the 20 - 60% OptiPrep™ gradient. 
Numbers (in %) indicate the OptiPrep™ 
concentration (diluted with H2O) in the different 
compartments. TX-100 = Triton X–100. 
 
A 1% TritonX-100 containing layer on top of 
the gradient was used to destroy the 
envelope structures resulting in a separation 
of the viral core pelleting at fractions with a 
higher density and the free proteins that can 
be found in fractions with lower density (18-
20). After ultracentrifugation 1mL fractions 
were collected from bottom to top and 
analyzed by immunoblotting (Fig. 6B). Both, 
A3C and Vpr.3C localized in the fractions 5 to 
8 with a density of 1.5 to 2 g/mL (Fig 6A and 
B). The reverse transcriptase (RT) is part of 
the viral core and therefore can be used to 
identify the core containing fractions of the 
gradient. Measuring the RT-activity for all 
fractions resulted in two peaks (Fig. 6A). The 
first peak of RT in both gradients was found 
in fractions co-localizing with A3C and 
Vpr.3C. RT activity was also detectable in the 
fractions on top of the gradient likely 
indicating free RT, possibly as result of a too 
harsh treatment with 1% TritonX-100 
resulting in disruption of some viral cores. 
The envelope protein (here VSV-
glycoprotein) was only seen in the top 
fractions of the gradient supporting a proper 
separation of free viral proteins from core 
structures (Fig. 6B).  
As A3C and Vpr.3C show identical sub-viral 
localizations, modes of encapsidation cannot 
explain the different restriction phenotypes of 
both proteins. It is more likely that HIV is able 
to circumvent the restriction of A3C by a virus 
encoded factor.  
 
HIV integrase as promising antagonist of 
A3C mediated restriction 
To investigate whether other HIV encoded 
factors besides the Vif protein might be able 
to counteract A3C, various viral proteins were 
analyzed on their potential to interact with 
A3C (data not shown). The HIV integrase 
(HIV-IN) turned out to be the most promising 
candidate. Integrase proteins of HIV-1 and 
SIVmac with a C-terminal 6x Histidin tag 
(His-tag) were expressed in E. coli and 
bound to Ni-NTA agarose (Fig. 7, upper 
panel). A3C was expressed in 293T cells and 
supplied to the Ni-NTA bound integrases. 
The HIV-IN showed interaction with A3C 
whereas the integrase of SIV was not able to 
bind A3C with the same efficiency (Fig. 7, 
lower panel). To test the binding of IN to 
Vpr.3C, both proteins, A3C and Vpr.3C, were 
expressed in 293T cells and added to Ni-NTA 
bound HIV-IN expressed in E. coli (Fig. 8A). 
In support of the model, by a direct 
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measurement of the relative light units from 
the immunoblot A3C was found to interact 
10-fold stronger to the HIV-IN compared to 
Vpr.3C (Fig. 8B). 
 
 
Fig. 6: OptiPrep™ gradients of HIV particles show no difference in sub-viral localization of A3C and Vpr.3C. 
(A) Determination of the RT activity in pg/mL (black lines) to display the localization the viral core containing 
fractions. The density (in g/mL) of each gradient fractions is displayed as dotted lines. (B) Immunoblot analysis 
to detect A3C and Vpr.3C (α-HA) in the different gradient fractions. An antibody against the VSV-glycoprotein 
(α-VSV-G) was used to determine the fractions that contain free viral proteins. 
   
DISCUSSION 
The antiviral activity of the ubiquitously 
expressed A3C (21-23)(18-20) is restricted to 
SIV ∆vif and retroelements. The Vif-
independent resistance of HIV-1 to A3C 
implicated an unknown viral mechanism to 
counteract A3 proteins. Unfortunately this 
study could not entirely elucidate the 
presumed novel viral mechanism, but the 
results indicate a new role for IN as an 
antagonist against A3C.  
A prerequisite for A3-mediated viral 
restriction is the incorporation of A3 proteins 
in newly budding virions. Although A3C is 
incorporated into HIV ∆vif particles no 
inhibition of viral infectivity could be 
observed. Fusion of the protein of HIV-1Vpr to 
A3C resulted in a restriction of HIV-1. The 
mechanism by which Vpr.3C and 3C.Vpr 
inhibit the viral infectivity is so far not entirely 
understood. However, this restriction of HIV-1 
by Vpr-A3C fusion proteins could not be 
counteracted through co-expression of Vif. It 
is thus possible that a sterical hindrance 
through the fused Vpr protein masked the Vif 
recognition site in A3C. But the Vif resistance 
to Vpr.3C and 3C.Vpr is difficult to explain. 
An inhibition of Vif binding by sterical 
hindrance by both, the N-terminal and the C-
terminal Vpr domain is mechanistically not 
obvious and a valuable topic for further 
experiments. Vpr itself behaved inert in this 
system and an effect of Vpr on the cell cycle 
(11, 12) can be excluded, because the fusion 
of Vpr to the enzymatic inactive A3C mutant 
C98S had no influence on viral infectivity. 
The Vpr fusion did also not change the sub-
viral localization of A3C in contrast to the 
results observed for A3A (7). 
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Fig. 7: A3C interacts with integrase of HIV. (A) 
Immunblot analysis of HIV and SIV integrase 
expression in E. coli and their binding to Ni-NTA 
agarose via a C-terminal His-tag using an α-His 
antibody. (B) Binding of HA-tagged A3C to the 
integrases was detected using an α-HA antibody.  
 
To investigate the sub-viral localization of 
A3C and Vpr.3C a fractionation via a 20-60% 
OptiPrep™ gradient was performed. 
Unexpectedly, both A3C and the Vpr.3C 
fusion protein were localized in fractions with 
similar density. Further a peak in RT activity 
could be observed in these fractions, strongly 
suggesting presence of viral core structures. 
These results exclude a random packaging of 
A3C into newly budding virions as a result of 
intensive overexpression in producer cells, 
because A3C and Vpr.3C are not found in 
fractions of free viral proteins after detergent 
treatment such as the envelope proteins. 
Therefore the incorporation of A3C and 
Vpr.3C into HIV virions must be a specific 
and directed process. As differences in the 
sub-viral localization cannot answer the 
question why Vpr.3C is antiviral active and 
A3C is not, one might speculate on Vpr.3C 
dimers which have a higher affinity to each 
other. This would be a reasonable 
explanation, as the Vpr protein itself forms 
dimers (24) and dimerization was shown to 
be crucial for antiviral activity of A3C (see 
Chapter I). Obviously HIV must have another 
factor besides Vif that is counteracting the 
antiviral activity of A3C. This so far unknown 
factor could destroy A3C dimers but is not 
potent enough to disrupt dimers of the 
Vpr.3C fusion protein. This factor must be 
 
Fig. 8: HIV-IN binds A3C more efficiently than 
Vpr.3C. (A) Immunoblot analysis of A3C and 
Vpr.3C expression in 293T cells (lysate) and the 
binding of both proteins to HIV-IN (bound) using 
an α-HA antibody. A3C and Vpr.3C were bound to 
comparable amounts of HIV-IN as determined via 
immunoblot analysis of Ni-NTA bound integrase 
using an α-His antibody. (B) Relative binding of 
A3C and Vpr.3C to the HIV-IN was quantified by 
direct measurement of the relative light units from 
the immunoblots in (A). Binding of A3C to HIV-IN 
was set to 100%. 
 
encoded by HIV, but not by SIV and this 
factor must show differences in the 
interaction with A3C and Vpr.3C. One of the 
first candidates was the Viral protein U (Vpu), 
as this protein is encoded by HIV, but not by 
SIV. Unfortunately A3C was not able to 
restrict the infectivity of vpu-deficient HIV 
(data not shown). After screening different 
other viral proteins for their physical 
interaction with A3C, the most promising 
candidate for an HIV encoded antagonist 
against A3C was thought to be the HIV-1 
Chapter II 
                                                                                 37   
integrase. Interaction studies of A3C with the 
integrases of HIV and SIV showed that A3C 
only interacts with the HIV integrase. This 
emphasizes the idea of an antagonist, 
because HIV ∆vif is not restricted by A3C, in 
contrast to SIV ∆vif. Additionally, the amino 
acid seqeuence of the HIV and SIV 
integrases are 57.8% identical, which 
facilitates different binding properties. 
Furthermore the fact, that the HIV restricting 
fusion protein Vpr.3C shows a 10-fold lower 
interaction to the HIV-IN supports this 
hypothesis. As interaction studies can only 
provide an indication on a possible function, 
an obvious experiment was to create an HIV 
∆vif luc reporter construct that encodes for 
the SIV-IN instead of its own integrase. This 
chimeric virus should therefore be restricted 
by A3C. Unfortunately, such a chimeric virus 
is unable to integrate into the host cell 
genome.  
Future experiments are necessary to 
emphazise the idea of the HIV integrase as 
antagonist of A3C mediated viral restriction. 
A fusion of Vpr to HIV-IN could deliver the 
protein together with A3C into SIV ∆vif 
particles, for instance. The presence of the 
HIV-IN in those SIV particles should then 
counteract the restriction of A3C against 
SIV ∆vif. As inhibition of dimerization could 
be an A3C neutralizing effect of the HIV-IN, 
experiments targeting the dimerization of 
A3C and Vpr.3C in presence and absence of 
the integrases of HIV and SIV could be 
performed.  
Altogether, these indications and early 
findings clearly lead to the integrase as 
potential A3C antagonist of HIV-1. 
 
 
 
 
Materials and Methods 
Plasmids. HA-tagged A3C and A3G constructs 
have been described previously (4, 25). To 
express the fusion proteins of VprHIV-1 and A3C 
the cDNA of Vpr of HIV-1 was fused either to the 
5´ start (Vpr.3C) or to the 3´ end (3C.Vpr) of A3C 
with a Gly4-Ser-linker in between. The fusion PCR 
was performed using KOD XL Polymerase 
(Novagen) according to the company’s 
instructions. The final fusion product was cloned 
into pcDNA 3.1 (+) from Invitrogen using BamHI 
and NotI restriction sites. Primer sequences are 
listed in Suppl. table S2. Viral vectors were 
produced by cotransfecting pSIVagm Δvif luc (17) 
or pNL 4-3 Δvif luc (26), pMD.G (a VSV.G 
expression plasmid), and supplemented (or not) 
with pcVif-SIVagm-V5 (27) or pc.Vif.HIV1-V5 (28). 
Protein expression and virus production 
293T cells were co-transfected with A3C, A3G or 
Vpr-fusion protein expression plasmids and  
pSIVagm Δvif luc or pNL 4-3 Δvif luc using 
Lipofectamin LTX (Invitrogen). To pseudotype the 
viral particles with the VSV-glycoprotein pMD.G 
was added. Vif expression plasmids were co-
transfected to put back Vif to counteract A3 
activity. 2days post-transfection virions and cells 
were harvested. Cells were immediately lysed in 
the appropiate volume of RIPA lysis buffer (25mM 
Tris, pH 8, 137mM NaCl, 1% glycerol, 0.1% SDS, 
0.5% sodiumdeoxycholate, 1% NP-40) for 10 min 
on ice and lysates were clarified by centrifugation 
in a table top centrifuge for 10 min at 4°C with 
14.000rpm. Cell lysates were subsequently used 
for immunoblot analysis to detect protein 
expression using an α-HA antibody (1:10.000 
dilution, Covance) and α-mouse horseradish 
peroxidase (1:7.500, Amersham Biosciences). 
Tubulin detection served as loading control 
(1:10.000, Sigma). Binding was visualized by ECL 
plus (Amersham Biosciences).  Harvested viral 
particles were filtered using 0.45µm MiniSart 
Filters (Sartorius) and downstream used for 
luciferase reportervirus assays or to analyze the 
incorporation of A3C, A3G and the fusion proteins 
into those particles. 
Chapter II 
                                                                                 38   
Luciferase reporter virus assay. To measure the 
infectivity of viral particles produced in the 
presence and absence of co-transfected proteins, 
the 2 days post transfection harvested virions 
were normalized by RT-concentration and used to 
transduce 2 × 103 HOS cells in a 96-well dish. 
Three days after transduction, intracellular 
luciferase activity was quantified using Steady Lite 
HTS (Perkin Elmer). Data are presented as the 
average counts per second of the triplicates ± 
standard deviation. RT concentration was 
quantified using the Lenti-RT Activity Assay 
(Cavidi Tech). 
Incorporation of A3 proteins into virions. To 
detect co-transfected proteins in viral particles, the 
2days post transfection harvested, filtered and RT 
-normalized virions were precipitated by 
ultracentrifugation over a 20% sucrose cushion 
and lysed using RIPA lysis buffer. These lysates 
of whole viral particles were then analyzed by 
immunoblot analysis for incorporation of A3 
proteins with an α-HA antibody as described 
above. Equal loading amounts were analyzed  
using the capsid monoclonal antibody AG 3.0 (29) 
in a 1:250 dilution. This antibody detects HIV p24 
and cross-reacts with SIV p27 and was therefore 
used in both cases.  
Determination of sub-viral localization. 
Harvested and filtered virion containing 
supernatants were pelleted over a 20% sucrose 
cushion by ultracentrifugation. The particles were 
then resuspended in 1 mL PBS. An 11 mL density 
gradient consisting of 20-60% OptiPrep™ (Sigma) 
was produced. On top of the gradient was a 1 mL 
layer of 10% OptiPrep™ and 1% TritonX-100 
followed by 2mL layer with 5% OptiPrep™ to build 
a boarder to the top 1 mL layer of resuspended 
viral particles. Ultracentrifugation of these 
gradients was performed for 20 hrs at 4°C with 
80.000 rcf. Subsequently eleven 1 mL fractions 
from bottom to top of the gradient were collected 
and either used for determination of RT 
concentration or for immunoblot analysis. The 
density of each fraction was calculated through 
measuring the refraction index at 20°C. Specific 
RT activity was quantified using the Lenti-RT 
Activity Assay (Cavidi Tech). Localization of A3 
proteins in the different fractions of the gradient 
was determined by immunoblot using the 
described α-HA antibody. To detect the envelope 
proteins outside the viral core an anti-VSV-G 
antibody (Sigma; 1:20.000) was used. 
A3C-Integrase interaction. The integrases were 
expressed from the plasmids pKB-IN6H (HIV-1 IN) 
(30) and pCP-SIVIN6H (SIVmac-IN; a gift from P. 
Cherepanov) in in the E. coli strain Rosetta BL21 
DE3. Empty expression vector pET-20b(+) (31) 
was used as negative control. Bacteria were 
transformed with the respective plasmid DNA and 
grown upon an OD of 0.5 at 600nm and 
heterologous protein expression was induced with 
0.1mM isopropyl 1-thio-β-D-galactopyranoside 
(IPTG). After over night incubation at room 
temperature cells were harvested, resuspended in 
binding buffer (50mM NaxHyPO4, 300mM NaCl, 
10mM imidazole) and lysed by sonification. Ni-
NTA Agarose (Invitrogen) was incubated with 
clarified lysates for 2 hours at 4 °C  and washed 5 
times with washing buffer (50mM NaxHyPO4, 
300mM NaCl, 20mM imidazole). 293T cells were 
transfected with A3C or Vpr.3C expression 
plasmids and cells were harvested 2 days post 
transfection, resuspended in binding buffer and 
lysed by sonification. The Ni-NTA agarose bound 
integrases were incubated with clarified lysates 
from 293T cells expressing A3C or Vpr.3C for 
3 hours at 4°C and washed 5 times with washing 
buffer. After washing Ni-NTA beads were 
incubated with elution buffer (50mM NaxHyPO4, 
300mM NaCl, 250mM imidazole) for 10min at 
room temperature to elute bound proteins. 
Proteins in the lysates and the elution fraction 
were analyzed by immunoblotting using an α-His-
C-terminal antibody (Invitrogen; 1:4000) 
(integrases) or the described α-HA antibody (A3C 
and Vpr.3C). Light units of the elution fractions 
were directly quantified from membranes 
incubated with ECL plus using the Lumianalyst 3.0 
software (Roche).      
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ABSTRACT 
Different retroviruses and retroelements are 
restricted by cellular cytidine deaminases of 
the APOBEC3 protein family. These proteins 
inhibit viral replication by deamination of 
cytidines to uridines on ssDNA during 
retroviral reverse transcription, a well 
characterized mechanism called editing. 
However, APOBEC3C’s (A3C) antiviral 
activity against Simian immunodeficiency 
virus (SIV) lacking its vif gene (SIV Δvif) was 
not caused by editing. 
This study aimed to find an alternative 
restriction mechanism of A3C against 
SIV Δvif. Different steps in viral replication 
that are potential targets of APOBEC3 
mediated restriction were examined. The 
results demonstrate, that A3C neither 
induces RNA-editing nor inhibits reverse 
transcription. Thus, A3C likely uses an 
additional, so far unidentified mechanism to 
restrict SIV Δvif. 
 
 
 
 
 
 
INTRODUCTION 
APOBEC3 proteins differ from each other in 
having one or two Zn2+-coordinating (Z) 
domains, that belong either to the Z1, Z2, or 
Z3 type (1). The best described member of 
the APOBEC3 protein family, APOBEC3G 
(A3G), comprises an N-terminal Z2- and a C-
terminal Z1-domain. Only the C-terminal 
domain mediates the enzymatic activity 
whereby retroviruses and transposable 
elements are inhibited (2-4). The restriction 
pattern of A3G is much broader than that of 
A3C (reviewed in (5)) which owns a single 
Z2-domain. A3G inhibits HIV Δvif mainly by 
deamination of cytidine to uridine of ssDNA 
formed during reverse transcription (6-9). 
These mutations either lead to degradation of 
viral DNA by DNA base repair enzymes 
(uracil DNA glycosylase and apurinic-
apyrimidinic endonuclease) (10), or to 
extensive G to A hypermutations on the 
coding strand of viral DNA. These editing 
events could result in alterations of the amino 
acid code or in introduction of inappropriate 
translation termination codons (7-9, 11). 
However, other mechanisms including 
inhibition of reverse transcription or 
Chapter III 
                                                                                 42   
integration have been discussed recently. 
(12-16).  
This study aimed to answer two questions: a) 
is the Zn2+-coordinating domain of A3C 
responsible for its antiviral activity against 
SIV ∆vif and b) what is the restriction 
mechanism of A3C. 
 
RESULTS 
The Zn2+-coordinating motif is the active 
site of A3C 
The two Zn2+-coordinating domains of 
APOBEC3G (A3G) display different 
functional properties. The N-terminal Z2-
domain (NTD) is responsible for virion 
incorporation of the protein and the C-
terminal Z1-domain (CTD) was shown to be 
the enzymatic active site of A3G (2, 4). To 
determine the function of the single Z2-
domain of A3C the zinc ion-binding amino 
acids were mutated as shown in Fig. 1.  
 
Fig. 1: Schematic overview of the point mutations 
in the Zn2+-coordinating domain (red) of A3C 
(grey). The single amino acids changes are shown 
as red letters. 
 
These A3C mutants were tested against SIV 
∆vif using luciferase reporter virus. VSV-G 
pseudotyped SIVagm luc ∆vif virions were 
produced in 293T cells in presence of wt or 
mutant A3C and in presence or absence of 
the Vif protein of SIV. 
 
Fig. 2: Mutations in the Zn2+ - coordinating domain results in loss of function proteins. (A) Antiviral activity of 
A3C wt and mutant proteins against  SIVagm Δvif luc and SIVagm luc, compared to non-transduced cells (mock) 
and vector only (control without A3C). (B) Immunoblot analysis of the expression, Vif-dependent degradation 
in producer cells and incorporation into virions of A3C wt and mutant proteins. Tubulin and p27 (capsid) 
served as loading control. 
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Normalized viral particles were used to 
transduce human osteosarcoma (HOS) cells. 
Intracellular luciferase activity in those cells 
determined the infectivity of used virions. 
Only wt A3C could reduce viral infectivity 
displayed as a decrease in luciferase activity 
(Fig. 2A). Mutation of any Zn2+-coordinating 
amino acid resulted in loss-of-function 
proteins, likely by destroying the active site. 
As these mutants were recognized by the Vif 
protein of SIV inducing their proteasomal 
degradation (Fig. 2B) they should not be 
subject to severe misfolding. Additionally, 
virion incorporation of A3C wt and mutant 
proteins was examined as this is a 
prerequisite for antiviral activity (Fig. 2B). The 
mutants H66R, E68Q, C98S were 
incorporated into viral particles similar to 
wt A3C, indicating that the non-restricting 
phenotype is not based on the exclusion of 
the mutants from the virions. Although the 
mutated proteins were packaged, mutations 
impaired their enzymatic active domain. 
Mutant C101S was packaged to a 
significantly lower extent and for this protein 
a low encapsidation into virions and/or the 
damaged active site can explain its inactivity 
against SIV Δvif. 
 
Viral DNA is not deaminated by A3C 
As deamination of viral cDNA is the most 
prominent mechanism of A3-mediated 
retroviral restriction, we examined whether 
DNA editing is also the reason for SIV ∆vif 
inhibition by A3C. Therefore pseudotyped 
SIV∆ vif luc virions, generated in presence or 
absence of A3C, were used to transduce 
HOS cells. At indicated time points post 
infection total DNA was isolated from those 
cells and a 600bp long fragment of the SIV 
gag gene was amplified via PCR. The 
resulting products were then sequenced and 
analyzed for G to A mutations (Fig. 3). The 
results display that A3C does not deaminate 
the viral cDNA of SIV ∆vif. DNA isolated at 4, 
9, 12 or 24 hours post infection in the 
presence of A3C showed G to A mutation 
ratios similar to that of the negative control 
(SIV ∆vif only) (Fig. 3). As a positive control, 
HOS cells were transduced with virions 
produced in the presence of A3G. PCR 
products of this infection showed the 
expected extensive hypermutation of the viral 
genome caused by A3G.  
 
A3C does not edit viral RNA 
As deamination of viral cDNA was likely not 
involved in the antiviral activity of A3C, 
another possible mechanism was editing of 
viral RNA prior to reverse transcription. Total 
RNA was isolated from cells transduced with 
VSV-G pseudotyped SIV∆vif luc virions 
produced in the presence or absence of A3C. 
After cDNA synthesis from total RNA a region 
including the primer binding site (PBS) was 
amplified and analyzed for mutations. 
Primers amplifying the PBS were chosen, as 
the initial step of reverse transcription starts 
with binding of the tRNA to the PBS (Fig. 4A) 
(17). The sequences (n=7) of SIV made in 
the presence of A3C showed that more non- 
specific (non C to U) mutations were 
detectable than mutations that could have 
resulted from A3C’s enzymatic activity (Fig. 
4B). Analyzing sequences after infection with 
SIV made in the absence of A3C ended up 
with a similar result. Taken together, A3C 
does neither deaminate viral cDNA nor viral 
RNA. 
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Fig. 3: A3C does not deaminate the genome of SIV ∆vif. Each G to A mutation is depicted as a dot. Five 
different clones were analyzed after different time points post infection. Editing ratios were calculated as the 
percentage of G to A mutations per 100 nt (grey). A3G served as positive control, SIV ∆vif only displays the 
background of A3-independend mutations. 
 
A3C does not block reverse transcription 
The products of retroviral reverse 
transcription (RT) can be divided in early and 
late RT products according to their 
appearance during the retroviral life cycle 
(18).   
 
Fig. 4: No deamination of SIV RNA detectable in 
the presence of A3C. (A) Primers are shown as 
black arrows flanking the PBS in the SIV genome. 
(B) Mutation ratios (in %) in presence (+) and 
absence (w/o) of A3C were calculated as C to U 
mutation on viral RNA per 100 nt. 
 
To investigate, if the RT reaction is 
influenced by A3C at all, we first analyzed  
late RT products. HOS cells were transduced 
with normalized amounts of virions (SIV∆vif 
luc) produced with or without A3C and 2, 4, 
24, 48 and 96 hours post infection total DNA 
was isolated from these cells. Via quantitative 
real time PCR the amount of viral, reverse 
transcribed cDNA was quantified as fg per 
100ng of total DNA using primers specific for 
late RT products. The results shown in Fig. 5 
indicate a delay in the appearance of late RT 
products of SIVΔvif made in the presence of 
A3C, whereas the overall amount of RT 
products remained the same. To proof that 
the observed A3C dependent decrease of 
luciferase activity in SIV∆vif luc infected cells 
after 3 days (Fig. 2) does not result from 
delayed viral replication, intracellular 
luciferase activity was also measured at day 
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4 post infection (Fig. 6). However, luciferase 
activity of virions produced in presence of 
A3C analyzed on day 3 and day 4 post 
infection were comparable. Thus, the 10 – 
100-fold antiviral effect of A3C likely cannot 
be explained by inhibition of reverse 
transcription.  
 
DISCUSSION 
The mechanisms responsible for the 
retroviral restriction by APOBEC3 proteins 
are still not completely solved. Besides 
deamination of the viral genome, other 
possibilities of A3-mediated restriction have 
been discussed recently (12-16), such as 
inhibition of reverse transcription or 
integration. In two domain APOBEC3 
proteins only one domain exhibits enzymatic 
activity, whereas the other domain is 
necessary for virion incorporation (2-4). Since 
A3C comprises only a single Zn2+-
coordinating domain, it was unclear how the 
protein manages both, encapsidation and 
antiviral activity. 
 
 
Fig. 5: Late reverse transcription products appear slightly later in the presence of A3C. Quantitative real-time 
PCR analysis of SIVagm Δvif luc late RT products after indicated time points post infection in target cells. 
Amount of reverse transcribed products was quantified as fg per 100ng of total isolated DNA. 
 
To answer whether the Zn2+-coordinating 
domain is the enzymatic active site of A3C, 
the crucial amino acids within this domain 
were mutated. These mutations resulted in a 
complete loss of antiviral activity although 
most of the mutants were efficiently 
incorporated, proofing that the single Zn2+-
coordinating domain is responsible for 
enzymatic activity. Later it was shown that a 
binding pocket proximal to this active site is 
crucial for RNA-dependent incorporation of 
A3C into viral particles (see Chapter I). 
Although in a bacterial deamination assay it 
was shown that A3C has the intrinsic 
capacity to deaminate cytidines (see Chapter 
I), there was no editing detectable in the 
context of SIV ∆vif infections in human cells. 
This result is in contrast to published data 
(19), where a very low editing ratio of A3C 
has been described. One could speculate 
about A3C inducing mutations resulting in 
viral restriction that might have occurred 
elsewhere in the viral genome instead of the 
analyzed part of the gag gene. This 
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possibility is very unlikely, as A3 proteins 
have certain recognition sequences (20) that 
consist of 2-4 nt being found within the whole 
viral genome. Also A3G clearly showed a 
strong deamination pattern within this part of 
the SIV genome. As the experimental results 
argue against cytidine deamination being the 
main mechanism of A3C-mediated restriction 
of SIV ∆vif, other possible molecular 
consequences of A3C activity were analyzed.  
To investigate inhibition of reverse 
transcription, two strategies were pursued. 
The first was RNA editing at the PBS. The 
RT reaction is initiated through binding of a 
tRNA at the PBS. The tRNA binding could be 
inhibited by destroying the recognition 
sequence of the PBS and reverse 
transcription would be blocked at the very 
first step. In agreement that A3 proteins act 
on ssDNA (20), RNA editing of A3C could not 
 
Fig. 6: Measurement of the antiviral activity of A3C against Δvi SIVagm luc at 3 or 4 days post infection (p. i.) in 
presence (white bars) or absence (black bars) of the Vif protein SIVagm showed no significant differences. 
 
be proven. The second approach was to 
examine whether the RT reaction was 
influenced through the presence of A3C. For 
A3G a decrease in HIV-1 reverse 
transcription products was determined when 
the protein was present (14, 21). It remains 
unclear whether this inhibition is caused by 
direct physical interaction with the viral 
enzyme reverse transcriptase. A3G could 
also bind to viral cDNA after first strand 
synthesis and thereby sterically block the 
synthesis of the second cDNA strand after 
strand transfer (15). To investigate whether 
A3C inhibits the RT reaction during infection, 
a quantitative PCR approach for late RT 
products was chosen amplifying a 600nt long 
part of the gag gene that is reverse 
transcribed at late stages of the dsDNA 
synthesis. Quantifying these late occurring 
RT products would show whether reverse 
transcription is inhibited at all. The results 
displayed a delay in the appearance of those 
late RT products caused by A3C. But as the 
overall amount of viral cDNA produced in 
presence or absence of A3C was 
comparable, it can be concluded that A3C 
does not inhibit reverse transcription. In the 
presence of A3C the RT products are 
moderately delayed. But this delay in the RT 
reaction did not correlate with a “restored” 
infectivity at later time points post infections. 
More experiments are required to test, 
Chapter III 
                                                                                 47   
whether the next steps in replication, nuclear 
import and integration are affected by A3C.  
 
Materials and Methods 
Plasmids. HA-tagged A3C and A3G constructs 
have been described previously (22, 23). The 
point mutations of A3C were inserted using site 
directed mutagenesis. Therefore A3C expression 
plasmid was used as template for a PCR reaction 
amplifying the whole plasmid with primers carrying 
those nucleotides to be changed. Primer 
sequences: H66R-5’: 5’-tctgcacgacaatgggtctca-3’, 
H66R-3’: 5’-gagacccgttgtcatgcaga-3’, E68Q-5’: 5’- 
cacctttgtgcatgacaatg-3’, E68Q-3’: 5’-atgcacaaag 
gtgcttcctc-3’, C98S-5’: 5’-tctggagaagggctccaagat-
3’, C98S-3’: 5’-gcccttctccagactgtgca-3’, C101S-5’: 
5’-ctgcagagtctgggcaaggg-3’ and C101S-3’: 5’- 
cagactctgcaggggaggtg-3’. After PCR the products 
were digested with DpnI to disrupt methylated, 
parental DNA and transformed into E. coli strain 
Top 10 (Invitrogen). Mutations were verified by 
sequencing. Viral vectors were produced by co-
transfection of pSIVagm Δvif luc (24) or pNL 4-3 
Δvif luc (25), pMD.G, a VSV-G expression 
plasmid, and supplemented (or not) with pcVif-
SIVagm-V5 (26) or pc.vif.HIV1-V5 (27). 
Protein expression and virus production. 293T 
cells were co-transfected with A3C expression 
plasmids and pSIVagmΔvif luc or pNL 4-3Δvif luc 
using Lipofectamine LTX (Invitrogen). To 
pseudotype the viral particles with the VSV-
glycoprotein pMD.G was co-transfected, too. Vif 
expression plasmids were co-transfected to 
counteract A3 activity. 2 days post transfection 
virions and cells were harvested. Cells were 
immediately lysed in an appropriate volume of 
RIPA lysis buffer (25mM Tris, pH 8, 137mM NaCl, 
1% glycerol, 0.1% SDS, 0.5% 
sodiumdeoxycholate, 1% NP-40) for 10min on ice 
and lysates were clarified by centrifugation in a 
table top centrifuge for 10min at 4°C with 
14.000rpm. Cell lysates were then used for 
immunoblot analysis to detect protein expression 
using an anti (α)-HA antibody (1:10.000, Covance) 
and α-mouse horseradish peroxidase (1:7.500, 
Amersham Biosciences). α -Tubulin was used as 
loading control and detected using α-tubulin 
antibody (1:10.000, Sigma). Signals were 
visualized by ECL plus (Amersham Biosciences). 
Harvested viral particles were filtered using 
0.45µm MiniSart Filters (Sartorius) and 
downstream used for luciferase reporter virus 
infections or to analyze the incorporation of A3C 
wt or mutant proteins into those particles. 
Luciferase reporter virus assay. To measure the 
infectivity of viral particles produced in the 
presence and absence of co-transfected proteins, 
2 days post transfection virions were harvested, 
normalized by RT-concentration and used to 
transduce 2×103 HOS cells in a 96-well dish. 
Three days after infection, intracellular luciferase 
activity was quantified using Steady Lite HTS 
(Perkin Elmer). Data are presented as the average 
counts per second of the triplicates ± standard 
deviation. RT concentration was quantified using 
the Lenti-RT Activity Assay (Cavidi Tech). 
Incorporation of A3 proteins into virions.  
To detect co-transfected proteins in viral particles, 
the 2 days post transfection harvested, filtered and 
RT -normalized virions were precipitated by 
ultracentrifugation over a 20% sucrose cushion 
and lysed using RIPA lysis buffer. These lysates 
of whole viral particles were then analyzed by 
immunoblot analysis for incorporation of A3 
proteins with an α-HA antibody as described 
above. Equal loading amounts were analyzed 
using the capsid monoclonal antibody AG 3.0 (28) 
(1:250). This antibody detects HIV p24 and cross-
reacts with SIV p27 and was therefore used in 
both cases. 
DNA Deamination assay. To detect deamination 
of viral cDNA, 2 days post transfection virions 
were harvested, filtered and RT normalized, as 
well as incubated with DNaseI (Roche) to remove 
residual plasmid DNA. HOS cells were transduced 
with these virions and 4, 9, 12 and 24 hours post 
infection total DNA was isolated using DNeasy 
Blood & Tissue Kit (QIAGEN). 300ng of total DNA 
was used as template to amplify a part of the gag 
gene with the primers CM101 (5‘-
caggctgagaaatctccagcag-3‘) and CM102 (5‘-
ccatgtctgccactaggtgtcgc-3‘) using Taq polymerase 
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(Fermentas). The PCR products were cloned into 
pJET1.2 cloning vector (Fermentas) and 
sequenced. G to A mutations were detected by 
aligning these sequences with the SIVagmTAN-1 
gag sequence. Editing ratios were calculated as G 
to A mutations per 100nt analyzed.  
RNA Deamination assay. Infection of HOS cells 
was performed similar to the DNA deamination 
assay. 6 hours post infection total RNA was 
isolated using RNeasy Kit (QIAGEN) and reverse 
transcribed into total cDNA with Super Script III 
Reverse Transcriptase (Invitrogen). 500ng of 
cDNA were used for the PCR reaction with 
primers PBS5´ (5‘-cttaagagtctatctgagcaag-3‘) and 
PBS3´ (5‘-gtaattaccatgtctgccact-3‘) flanking the 
primer binding site. PCR products were analyzed 
similar to the DNA deamination assay. 
Quantitative PCR to detect late RT products. 
HOS cells were transduced with SIV Δvif virions 
produced in presence and absence of A3C. At 2, 
4, 9, 24, 48 and 96 hours post infection total DNA 
was isolated using DNeasy Blood & Tissue Kit 
(QIAGEN). 100ng of each total DNA were used for 
a quantitative real-time PCR to detect late RT 
products with the primers: CS: 5’-cactcgg 
cactgtcaggga-3’ and CR: 5’-ggttctagcgggctcaata 
cttctat-3’. Specificity of the products was 
determined by use of Fluorescein (Fl) and Light 
Cycler Red 640 (LC) labeled hybridization probes: 
C-Fl: 5’-tgatactttttctttccgttcgggcg—Fl-3’ and 5’-
LC—aagcgtattttctcaaatgtgtccaaattcc-3’. The 
following cycling conditions were used: 50 cycles 
with 95°C for 10sec, 57°C for 20sec and 72°C for 
10sec in Light Cycler 3 instrument from Roche. 
The amount of late RT products in fg per 100ng 
was determined by standardization of each run 
with a serial dilution of pSIVagm Δvif plasmid. 
Therefore 10fg, 100fg, 1pg and 10pg of plasmid 
DNA were used.  
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Additional Material and Methods 
Model refinement and evaluation. 
MODELLER 9v4 implements the dynamic programming algorithm by a variable gap penalty (1): 
Based on the PDB template structures, gaps were penalized differentially and favored in solvent-
exposed loops and surface regions compared to secondary structure elements and core regions 
and therefore placed in a preferential structural context. Penalties were given as a vector with 
values previously suggested as optimal for the sequence identity found in the alignment (1). 
REDUCE (2) was applied to add hydrogens to all initial models obtained by MODELLER 9v4 (24, 
42). The models were subsequently energy-minimized, using the CHARMM22 forcefield (3), 
generalized Born implicit solvent model and a gradient descent algorithm as implemented in MOE 
2006.08 (Chemical Computing Group, Montreal, Canada): first hydrogens only, then sidechains, 
finally backbone atoms, tethered by a force constant of 0.1. PROCHECK v.3.5 (4) was used to 
evaluate both the minimized models and the template structures. The models with fewest violations 
of backbone angles were equilibrated by Molecular Dynamics (MD) simulation. The MD simulations 
were carried out by NAMD Scalable Molecular Dynamics (5) in a water sphere with harmonic 
boundary conditions, CHARMM22 force field, and Langevin Dynamics in a canonic NVT ensemble, 
2 fs timestep. After initial minimization for 10,000 discrete steps, the simulation was run for 20 ns at 
310 K. The resulting trajectory was visualized and evaluated using VMD Visual Molecular 
Dynamics (6). The ANOLEA software (27), implementing a knowledge-based residue-wise pseudo-
potential, was utilized to generate ”energy” profiles of the final model structures of A3C and the 
respective PDB templates, using five-residue window averaging. Differences between superposed 
structures were quantified as root mean square deviation (RMSD) of Cα atoms. Pictures of protein 
models were generated using UCSF Chimera v1 (7).  
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Figure S1. Ramachandran plots of (a) human APOBEC2 (A2), chain B (crystal structure), (b) A2-
derived model structure of human APOBEC3C (A3C), (c) human APOBEC3G, C terminal domain 
(A3G-CD) and (d) A3G-CD-derived model structure of A3C. Stereochemical regions are colored 
red (most favourable), bright yellow (additionally allowed), pale yellow (generously allowed) and 
white (disallowed). Amino acids violating stereochemistry are indicated as red squares and 
numbered according to original PDB files / A3C amino acid sequence. Glycins are indicated as 
black triangles, all remaining amino acids as black squares. 
(A2 crystal structure: 87.6% most favored, 11.8% additionally allowed, 0.6% generously allowed, 
0% disallowed; A3G-CD solution structure: 84.8, 11.0, 2.4, 1.8%, respectively)  
(A2-derived model: 83.7% most favorable, 14.0% additionally allowed, 0.6% generously allowed, 
1.8% disallowed; A3G-CD-derived model: 84.9, 9.9, 2.3, 2.9%, respectively, with all generously 
and disallowed residues being in loop regions or the N-terminus modeled without template) 
The global sequence identity of A3C and A2 is 30.2%, for secondary structure regions it is only 
marginally higher (32.8%). The global sequence identity of A3C and A3G-CD is 40.5%, but 
significantly higher (53.5%) for secondary structure regions. 
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Figure S2. Alignment of human APOBEC3C (A3C) to human APOBEC2 (A2) (a), human 
APOBEC3G, C-terminal domain (A3G-CD) (b) and human APOBEC3G, N-terminal domain (A3G-
ND) (c). Secondary structure of A2 and A3G-CD as assigned by DSSP (H, helix; E, strand; else 
loop) are indicated above the sequences, if available. Identical amino acids are given in bold and 
denoted by ‘ | ‘, gaps in the respective sequence by ‘-’. The Zn2+-coordinating deaminase motif is 
highlighted (red box). A2 and A3C share 30.2% identical amino acids, A3G-CD and A3C 40.5%, 
A3G-ND and A3C 44.0%. 
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Figure S3. ANOLEA-profiles for (a) the A2 crystal structure, (b) the A3G-CTD crystal structure, (c) 
the A2-based model of A3C and (d) the A3G-CTD-based model structure of A3C. ANOLEA-
“energies” represent a knowledge-based pseudo-potential and are plotted for each sequence 
position of the respective protein model. 
 
 
 
 
 
 
 
 
Figure S4. Equilibration of human APOBEC3C (A3C). Development of the total (a), van-der-Waals 
(b) and electrostatic energy (c) of the human A3C model over time. Energies are shown over the 
first 25 picoseconds (ps). During the course of the total 20 ns of simulation, energies are stationary 
(not shown). 
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Figure S5. Evaluation of MD simulation of APOBEC structures. Development of the deviation 
of the conformation of the crystal structure of A2 (a), the A2-derived model of A3C (b), the crystal 
structure of A3G-CTD (c), and the A3G-CTD-derived model of A3C (d) with respect to the starting 
conformation over the course of the simulation, measured in Å root mean square deviation 
(RMSD). Simulations have been replicated three times (black, blue, red curve). Experimental (blue) 
and simulated B-factors (red) of C-alpha atoms of human APOBEC2, chain B (e) and human 
APOBEC3G, C-terminal domain (f). 
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Figure S6. (a) Quantification of light units from immunoblot (IB) of bound V5-tagged wt A3C to 
indicated co-transfected HA-tagged wt A3C or W74A. Numbers indicate the signal intensity of V5-
tagged wt A3C bound to W74A relative to the amount of V5-tagged wt A3C bound to HA-tagged wt 
A3C. Background interaction of V5-tagged wt A3C with anti-HA affinity beads was determined 
equally. (b) Immunoblot analysis of crosslinks of wt A3C or W74A in total cell lysate of transfected 
cells. Cleared cell lysate was treated with 50mM NEM for 2hrs at room temperature and separated 
on 4-12% SDS-PAGE. A3C wt or mutant were detected by an anti(α)-HA antibody. 
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